| Our Lady Of Fatima Hospital | |
|
200 High Service Ave North Providence RI 02904-5113 | |
| (401) 456-3000 | |
| (401) 456-3028 |
| Full Name | Our Lady Of Fatima Hospital |
|---|---|
| Speciality | Internal Medicine |
| Location | 200 High Service Ave, North Providence, Rhode Island |
| Authorized Official Name and Position | Robert Jon Elders (SECRETARY) |
| Authorized Official Contact | 7147881249 |
| Accepts Medicare Insurance | Yes. This clinic participates in medicare program and accept medicare insurance. |
| Mailing Address | Practice Location Address |
|---|---|
| Our Lady Of Fatima Hospital 200 High Service Ave North Providence RI 02904-5113 Ph: (401) 456-3000 | Our Lady Of Fatima Hospital 200 High Service Ave North Providence RI 02904-5113 Ph: (401) 456-3000 |
| NPI Number | 1588089759 |
|---|---|
| Provider Enumeration Date | 02/25/2014 |
| Last Update Date | 12/21/2020 |
| Certification Date | 12/21/2020 |
| Medicare PECOS PAC ID | 7315179314 |
|---|---|
| Medicare Enrollment ID | O20140722001928 |
News Archive
Baxa Corporation announces the launch of a new program for sourcing its IntelliFill i.v. Automation and IntelliFlowRx Pharmacy Workflow Manager products. The Baxa IntelliSource(TM) program offers health-system pharmacies access to the automation and software they need to ensure that each dose dispensed is safe and accurate - without making capital investments, paying one-time setup fees or signing capital leases.
The Medical Innovation Bill tabled by Lord Saatchi and currently making its way through the UK's House of Lords "strikes at the heart of evidence-based medicine" and risks "opening the door to the use of less proven, or unproven, approaches such as complementary or alternative medicine", according to a new Editorial published in The Lancet Oncology.
Around 20% of breast cancer patients do not complete prescribed endocrine therapy, researchers report at the ESMO Asia 2016 Congress in Singapore.1 The study in over 5,500 women found that younger patients and those who had taken hormone replacement therapy (HRT) were less likely to adhere to their medicine.
NextSource Biotechnology, LLC announced today that Gleostine (lomustine) 5 mg capsules has been approved by the U.S. Food and Drug Administration and is now commercially available in the United States.
› Verified 5 days ago
| Identifier | Type | State | Issuer |
|---|---|---|---|
| 1588089759 | NPI | - | NPPES |
| Provider Name | William J Beliveau |
|---|---|
| Provider Type | Practitioner - Pulmonary Disease |
| Provider Identifiers | NPI Number: 1578588067 PECOS PAC ID: 4688573264 Enrollment ID: I20040102000373 |
News Archive
Baxa Corporation announces the launch of a new program for sourcing its IntelliFill i.v. Automation and IntelliFlowRx Pharmacy Workflow Manager products. The Baxa IntelliSource(TM) program offers health-system pharmacies access to the automation and software they need to ensure that each dose dispensed is safe and accurate - without making capital investments, paying one-time setup fees or signing capital leases.
The Medical Innovation Bill tabled by Lord Saatchi and currently making its way through the UK's House of Lords "strikes at the heart of evidence-based medicine" and risks "opening the door to the use of less proven, or unproven, approaches such as complementary or alternative medicine", according to a new Editorial published in The Lancet Oncology.
Around 20% of breast cancer patients do not complete prescribed endocrine therapy, researchers report at the ESMO Asia 2016 Congress in Singapore.1 The study in over 5,500 women found that younger patients and those who had taken hormone replacement therapy (HRT) were less likely to adhere to their medicine.
NextSource Biotechnology, LLC announced today that Gleostine (lomustine) 5 mg capsules has been approved by the U.S. Food and Drug Administration and is now commercially available in the United States.
› Verified 5 days ago
| Provider Name | Jack P Mourad |
|---|---|
| Provider Type | Practitioner - Emergency Medicine |
| Provider Identifiers | NPI Number: 1912972050 PECOS PAC ID: 0547157513 Enrollment ID: I20040303000830 |
News Archive
Baxa Corporation announces the launch of a new program for sourcing its IntelliFill i.v. Automation and IntelliFlowRx Pharmacy Workflow Manager products. The Baxa IntelliSource(TM) program offers health-system pharmacies access to the automation and software they need to ensure that each dose dispensed is safe and accurate - without making capital investments, paying one-time setup fees or signing capital leases.
The Medical Innovation Bill tabled by Lord Saatchi and currently making its way through the UK's House of Lords "strikes at the heart of evidence-based medicine" and risks "opening the door to the use of less proven, or unproven, approaches such as complementary or alternative medicine", according to a new Editorial published in The Lancet Oncology.
Around 20% of breast cancer patients do not complete prescribed endocrine therapy, researchers report at the ESMO Asia 2016 Congress in Singapore.1 The study in over 5,500 women found that younger patients and those who had taken hormone replacement therapy (HRT) were less likely to adhere to their medicine.
NextSource Biotechnology, LLC announced today that Gleostine (lomustine) 5 mg capsules has been approved by the U.S. Food and Drug Administration and is now commercially available in the United States.
› Verified 5 days ago
| Provider Name | Edward J Gauthier |
|---|---|
| Provider Type | Practitioner - Internal Medicine |
| Provider Identifiers | NPI Number: 1750475992 PECOS PAC ID: 9537156070 Enrollment ID: I20040427001617 |
News Archive
Baxa Corporation announces the launch of a new program for sourcing its IntelliFill i.v. Automation and IntelliFlowRx Pharmacy Workflow Manager products. The Baxa IntelliSource(TM) program offers health-system pharmacies access to the automation and software they need to ensure that each dose dispensed is safe and accurate - without making capital investments, paying one-time setup fees or signing capital leases.
The Medical Innovation Bill tabled by Lord Saatchi and currently making its way through the UK's House of Lords "strikes at the heart of evidence-based medicine" and risks "opening the door to the use of less proven, or unproven, approaches such as complementary or alternative medicine", according to a new Editorial published in The Lancet Oncology.
Around 20% of breast cancer patients do not complete prescribed endocrine therapy, researchers report at the ESMO Asia 2016 Congress in Singapore.1 The study in over 5,500 women found that younger patients and those who had taken hormone replacement therapy (HRT) were less likely to adhere to their medicine.
NextSource Biotechnology, LLC announced today that Gleostine (lomustine) 5 mg capsules has been approved by the U.S. Food and Drug Administration and is now commercially available in the United States.
› Verified 5 days ago
| Provider Name | R James Koness |
|---|---|
| Provider Type | Practitioner - Surgical Oncology |
| Provider Identifiers | NPI Number: 1750348157 PECOS PAC ID: 1052302635 Enrollment ID: I20040521000684 |
News Archive
Baxa Corporation announces the launch of a new program for sourcing its IntelliFill i.v. Automation and IntelliFlowRx Pharmacy Workflow Manager products. The Baxa IntelliSource(TM) program offers health-system pharmacies access to the automation and software they need to ensure that each dose dispensed is safe and accurate - without making capital investments, paying one-time setup fees or signing capital leases.
The Medical Innovation Bill tabled by Lord Saatchi and currently making its way through the UK's House of Lords "strikes at the heart of evidence-based medicine" and risks "opening the door to the use of less proven, or unproven, approaches such as complementary or alternative medicine", according to a new Editorial published in The Lancet Oncology.
Around 20% of breast cancer patients do not complete prescribed endocrine therapy, researchers report at the ESMO Asia 2016 Congress in Singapore.1 The study in over 5,500 women found that younger patients and those who had taken hormone replacement therapy (HRT) were less likely to adhere to their medicine.
NextSource Biotechnology, LLC announced today that Gleostine (lomustine) 5 mg capsules has been approved by the U.S. Food and Drug Administration and is now commercially available in the United States.
› Verified 5 days ago
| Provider Name | Saira Hussain |
|---|---|
| Provider Type | Practitioner - Internal Medicine |
| Provider Identifiers | NPI Number: 1891749016 PECOS PAC ID: 9133103534 Enrollment ID: I20040615000103 |
News Archive
Baxa Corporation announces the launch of a new program for sourcing its IntelliFill i.v. Automation and IntelliFlowRx Pharmacy Workflow Manager products. The Baxa IntelliSource(TM) program offers health-system pharmacies access to the automation and software they need to ensure that each dose dispensed is safe and accurate - without making capital investments, paying one-time setup fees or signing capital leases.
The Medical Innovation Bill tabled by Lord Saatchi and currently making its way through the UK's House of Lords "strikes at the heart of evidence-based medicine" and risks "opening the door to the use of less proven, or unproven, approaches such as complementary or alternative medicine", according to a new Editorial published in The Lancet Oncology.
Around 20% of breast cancer patients do not complete prescribed endocrine therapy, researchers report at the ESMO Asia 2016 Congress in Singapore.1 The study in over 5,500 women found that younger patients and those who had taken hormone replacement therapy (HRT) were less likely to adhere to their medicine.
NextSource Biotechnology, LLC announced today that Gleostine (lomustine) 5 mg capsules has been approved by the U.S. Food and Drug Administration and is now commercially available in the United States.
› Verified 5 days ago
| Provider Name | Ghulam Mustafa Surti |
|---|---|
| Provider Type | Practitioner - Psychiatry |
| Provider Identifiers | NPI Number: 1861499675 PECOS PAC ID: 1456331354 Enrollment ID: I20040721001569 |
News Archive
Baxa Corporation announces the launch of a new program for sourcing its IntelliFill i.v. Automation and IntelliFlowRx Pharmacy Workflow Manager products. The Baxa IntelliSource(TM) program offers health-system pharmacies access to the automation and software they need to ensure that each dose dispensed is safe and accurate - without making capital investments, paying one-time setup fees or signing capital leases.
The Medical Innovation Bill tabled by Lord Saatchi and currently making its way through the UK's House of Lords "strikes at the heart of evidence-based medicine" and risks "opening the door to the use of less proven, or unproven, approaches such as complementary or alternative medicine", according to a new Editorial published in The Lancet Oncology.
Around 20% of breast cancer patients do not complete prescribed endocrine therapy, researchers report at the ESMO Asia 2016 Congress in Singapore.1 The study in over 5,500 women found that younger patients and those who had taken hormone replacement therapy (HRT) were less likely to adhere to their medicine.
NextSource Biotechnology, LLC announced today that Gleostine (lomustine) 5 mg capsules has been approved by the U.S. Food and Drug Administration and is now commercially available in the United States.
› Verified 5 days ago
| Provider Name | Chelsy Caren |
|---|---|
| Provider Type | Practitioner - Obstetrics/gynecology |
| Provider Identifiers | NPI Number: 1346207602 PECOS PAC ID: 3072588490 Enrollment ID: I20040830000684 |
News Archive
Baxa Corporation announces the launch of a new program for sourcing its IntelliFill i.v. Automation and IntelliFlowRx Pharmacy Workflow Manager products. The Baxa IntelliSource(TM) program offers health-system pharmacies access to the automation and software they need to ensure that each dose dispensed is safe and accurate - without making capital investments, paying one-time setup fees or signing capital leases.
The Medical Innovation Bill tabled by Lord Saatchi and currently making its way through the UK's House of Lords "strikes at the heart of evidence-based medicine" and risks "opening the door to the use of less proven, or unproven, approaches such as complementary or alternative medicine", according to a new Editorial published in The Lancet Oncology.
Around 20% of breast cancer patients do not complete prescribed endocrine therapy, researchers report at the ESMO Asia 2016 Congress in Singapore.1 The study in over 5,500 women found that younger patients and those who had taken hormone replacement therapy (HRT) were less likely to adhere to their medicine.
NextSource Biotechnology, LLC announced today that Gleostine (lomustine) 5 mg capsules has been approved by the U.S. Food and Drug Administration and is now commercially available in the United States.
› Verified 5 days ago
| Provider Name | Karen Mcdonald |
|---|---|
| Provider Type | Practitioner - Certified Clinical Nurse Specialist (cns) |
| Provider Identifiers | NPI Number: 1841236718 PECOS PAC ID: 5890762470 Enrollment ID: I20040914000004 |
News Archive
Baxa Corporation announces the launch of a new program for sourcing its IntelliFill i.v. Automation and IntelliFlowRx Pharmacy Workflow Manager products. The Baxa IntelliSource(TM) program offers health-system pharmacies access to the automation and software they need to ensure that each dose dispensed is safe and accurate - without making capital investments, paying one-time setup fees or signing capital leases.
The Medical Innovation Bill tabled by Lord Saatchi and currently making its way through the UK's House of Lords "strikes at the heart of evidence-based medicine" and risks "opening the door to the use of less proven, or unproven, approaches such as complementary or alternative medicine", according to a new Editorial published in The Lancet Oncology.
Around 20% of breast cancer patients do not complete prescribed endocrine therapy, researchers report at the ESMO Asia 2016 Congress in Singapore.1 The study in over 5,500 women found that younger patients and those who had taken hormone replacement therapy (HRT) were less likely to adhere to their medicine.
NextSource Biotechnology, LLC announced today that Gleostine (lomustine) 5 mg capsules has been approved by the U.S. Food and Drug Administration and is now commercially available in the United States.
› Verified 5 days ago
| Provider Name | Andrea Goldfarb |
|---|---|
| Provider Type | Practitioner - Emergency Medicine |
| Provider Identifiers | NPI Number: 1609853290 PECOS PAC ID: 3072582493 Enrollment ID: I20041001000004 |
News Archive
Baxa Corporation announces the launch of a new program for sourcing its IntelliFill i.v. Automation and IntelliFlowRx Pharmacy Workflow Manager products. The Baxa IntelliSource(TM) program offers health-system pharmacies access to the automation and software they need to ensure that each dose dispensed is safe and accurate - without making capital investments, paying one-time setup fees or signing capital leases.
The Medical Innovation Bill tabled by Lord Saatchi and currently making its way through the UK's House of Lords "strikes at the heart of evidence-based medicine" and risks "opening the door to the use of less proven, or unproven, approaches such as complementary or alternative medicine", according to a new Editorial published in The Lancet Oncology.
Around 20% of breast cancer patients do not complete prescribed endocrine therapy, researchers report at the ESMO Asia 2016 Congress in Singapore.1 The study in over 5,500 women found that younger patients and those who had taken hormone replacement therapy (HRT) were less likely to adhere to their medicine.
NextSource Biotechnology, LLC announced today that Gleostine (lomustine) 5 mg capsules has been approved by the U.S. Food and Drug Administration and is now commercially available in the United States.
› Verified 5 days ago
| Provider Name | Walter A Hollinger |
|---|---|
| Provider Type | Practitioner - Internal Medicine |
| Provider Identifiers | NPI Number: 1679663405 PECOS PAC ID: 0648238584 Enrollment ID: I20041227000049 |
News Archive
Baxa Corporation announces the launch of a new program for sourcing its IntelliFill i.v. Automation and IntelliFlowRx Pharmacy Workflow Manager products. The Baxa IntelliSource(TM) program offers health-system pharmacies access to the automation and software they need to ensure that each dose dispensed is safe and accurate - without making capital investments, paying one-time setup fees or signing capital leases.
The Medical Innovation Bill tabled by Lord Saatchi and currently making its way through the UK's House of Lords "strikes at the heart of evidence-based medicine" and risks "opening the door to the use of less proven, or unproven, approaches such as complementary or alternative medicine", according to a new Editorial published in The Lancet Oncology.
Around 20% of breast cancer patients do not complete prescribed endocrine therapy, researchers report at the ESMO Asia 2016 Congress in Singapore.1 The study in over 5,500 women found that younger patients and those who had taken hormone replacement therapy (HRT) were less likely to adhere to their medicine.
NextSource Biotechnology, LLC announced today that Gleostine (lomustine) 5 mg capsules has been approved by the U.S. Food and Drug Administration and is now commercially available in the United States.
› Verified 5 days ago
| Provider Name | Tara A Nimiroski |
|---|---|
| Provider Type | Practitioner - Nurse Practitioner |
| Provider Identifiers | NPI Number: 1295750867 PECOS PAC ID: 0941250203 Enrollment ID: I20050125000867 |
News Archive
Baxa Corporation announces the launch of a new program for sourcing its IntelliFill i.v. Automation and IntelliFlowRx Pharmacy Workflow Manager products. The Baxa IntelliSource(TM) program offers health-system pharmacies access to the automation and software they need to ensure that each dose dispensed is safe and accurate - without making capital investments, paying one-time setup fees or signing capital leases.
The Medical Innovation Bill tabled by Lord Saatchi and currently making its way through the UK's House of Lords "strikes at the heart of evidence-based medicine" and risks "opening the door to the use of less proven, or unproven, approaches such as complementary or alternative medicine", according to a new Editorial published in The Lancet Oncology.
Around 20% of breast cancer patients do not complete prescribed endocrine therapy, researchers report at the ESMO Asia 2016 Congress in Singapore.1 The study in over 5,500 women found that younger patients and those who had taken hormone replacement therapy (HRT) were less likely to adhere to their medicine.
NextSource Biotechnology, LLC announced today that Gleostine (lomustine) 5 mg capsules has been approved by the U.S. Food and Drug Administration and is now commercially available in the United States.
› Verified 5 days ago
| Provider Name | Michele S Nardi |
|---|---|
| Provider Type | Practitioner - Certified Clinical Nurse Specialist (cns) |
| Provider Identifiers | NPI Number: 1891880878 PECOS PAC ID: 0749230324 Enrollment ID: I20050207000497 |
News Archive
Baxa Corporation announces the launch of a new program for sourcing its IntelliFill i.v. Automation and IntelliFlowRx Pharmacy Workflow Manager products. The Baxa IntelliSource(TM) program offers health-system pharmacies access to the automation and software they need to ensure that each dose dispensed is safe and accurate - without making capital investments, paying one-time setup fees or signing capital leases.
The Medical Innovation Bill tabled by Lord Saatchi and currently making its way through the UK's House of Lords "strikes at the heart of evidence-based medicine" and risks "opening the door to the use of less proven, or unproven, approaches such as complementary or alternative medicine", according to a new Editorial published in The Lancet Oncology.
Around 20% of breast cancer patients do not complete prescribed endocrine therapy, researchers report at the ESMO Asia 2016 Congress in Singapore.1 The study in over 5,500 women found that younger patients and those who had taken hormone replacement therapy (HRT) were less likely to adhere to their medicine.
NextSource Biotechnology, LLC announced today that Gleostine (lomustine) 5 mg capsules has been approved by the U.S. Food and Drug Administration and is now commercially available in the United States.
› Verified 5 days ago
| Provider Name | Wajahat Faheem |
|---|---|
| Provider Type | Practitioner - Psychiatry |
| Provider Identifiers | NPI Number: 1053323691 PECOS PAC ID: 6608827357 Enrollment ID: I20050210000058 |
News Archive
Baxa Corporation announces the launch of a new program for sourcing its IntelliFill i.v. Automation and IntelliFlowRx Pharmacy Workflow Manager products. The Baxa IntelliSource(TM) program offers health-system pharmacies access to the automation and software they need to ensure that each dose dispensed is safe and accurate - without making capital investments, paying one-time setup fees or signing capital leases.
The Medical Innovation Bill tabled by Lord Saatchi and currently making its way through the UK's House of Lords "strikes at the heart of evidence-based medicine" and risks "opening the door to the use of less proven, or unproven, approaches such as complementary or alternative medicine", according to a new Editorial published in The Lancet Oncology.
Around 20% of breast cancer patients do not complete prescribed endocrine therapy, researchers report at the ESMO Asia 2016 Congress in Singapore.1 The study in over 5,500 women found that younger patients and those who had taken hormone replacement therapy (HRT) were less likely to adhere to their medicine.
NextSource Biotechnology, LLC announced today that Gleostine (lomustine) 5 mg capsules has been approved by the U.S. Food and Drug Administration and is now commercially available in the United States.
› Verified 5 days ago
| Provider Name | Deborah M Valletta |
|---|---|
| Provider Type | Practitioner - Clinical Social Worker |
| Provider Identifiers | NPI Number: 1174650576 PECOS PAC ID: 7214962091 Enrollment ID: I20050929001067 |
News Archive
Baxa Corporation announces the launch of a new program for sourcing its IntelliFill i.v. Automation and IntelliFlowRx Pharmacy Workflow Manager products. The Baxa IntelliSource(TM) program offers health-system pharmacies access to the automation and software they need to ensure that each dose dispensed is safe and accurate - without making capital investments, paying one-time setup fees or signing capital leases.
The Medical Innovation Bill tabled by Lord Saatchi and currently making its way through the UK's House of Lords "strikes at the heart of evidence-based medicine" and risks "opening the door to the use of less proven, or unproven, approaches such as complementary or alternative medicine", according to a new Editorial published in The Lancet Oncology.
Around 20% of breast cancer patients do not complete prescribed endocrine therapy, researchers report at the ESMO Asia 2016 Congress in Singapore.1 The study in over 5,500 women found that younger patients and those who had taken hormone replacement therapy (HRT) were less likely to adhere to their medicine.
NextSource Biotechnology, LLC announced today that Gleostine (lomustine) 5 mg capsules has been approved by the U.S. Food and Drug Administration and is now commercially available in the United States.
› Verified 5 days ago
| Provider Name | Joanne M Gibbons |
|---|---|
| Provider Type | Practitioner - Clinical Social Worker |
| Provider Identifiers | NPI Number: 1982790291 PECOS PAC ID: 3173549102 Enrollment ID: I20051019000852 |
News Archive
Baxa Corporation announces the launch of a new program for sourcing its IntelliFill i.v. Automation and IntelliFlowRx Pharmacy Workflow Manager products. The Baxa IntelliSource(TM) program offers health-system pharmacies access to the automation and software they need to ensure that each dose dispensed is safe and accurate - without making capital investments, paying one-time setup fees or signing capital leases.
The Medical Innovation Bill tabled by Lord Saatchi and currently making its way through the UK's House of Lords "strikes at the heart of evidence-based medicine" and risks "opening the door to the use of less proven, or unproven, approaches such as complementary or alternative medicine", according to a new Editorial published in The Lancet Oncology.
Around 20% of breast cancer patients do not complete prescribed endocrine therapy, researchers report at the ESMO Asia 2016 Congress in Singapore.1 The study in over 5,500 women found that younger patients and those who had taken hormone replacement therapy (HRT) were less likely to adhere to their medicine.
NextSource Biotechnology, LLC announced today that Gleostine (lomustine) 5 mg capsules has been approved by the U.S. Food and Drug Administration and is now commercially available in the United States.
› Verified 5 days ago
| Provider Name | David Kroessler |
|---|---|
| Provider Type | Practitioner - Psychiatry |
| Provider Identifiers | NPI Number: 1740211168 PECOS PAC ID: 7214838705 Enrollment ID: I20051209000439 |
News Archive
Baxa Corporation announces the launch of a new program for sourcing its IntelliFill i.v. Automation and IntelliFlowRx Pharmacy Workflow Manager products. The Baxa IntelliSource(TM) program offers health-system pharmacies access to the automation and software they need to ensure that each dose dispensed is safe and accurate - without making capital investments, paying one-time setup fees or signing capital leases.
The Medical Innovation Bill tabled by Lord Saatchi and currently making its way through the UK's House of Lords "strikes at the heart of evidence-based medicine" and risks "opening the door to the use of less proven, or unproven, approaches such as complementary or alternative medicine", according to a new Editorial published in The Lancet Oncology.
Around 20% of breast cancer patients do not complete prescribed endocrine therapy, researchers report at the ESMO Asia 2016 Congress in Singapore.1 The study in over 5,500 women found that younger patients and those who had taken hormone replacement therapy (HRT) were less likely to adhere to their medicine.
NextSource Biotechnology, LLC announced today that Gleostine (lomustine) 5 mg capsules has been approved by the U.S. Food and Drug Administration and is now commercially available in the United States.
› Verified 5 days ago
| Provider Name | Maureen Harkavy |
|---|---|
| Provider Type | Practitioner - Psychiatry |
| Provider Identifiers | NPI Number: 1417911207 PECOS PAC ID: 9830104116 Enrollment ID: I20060207000900 |
News Archive
Baxa Corporation announces the launch of a new program for sourcing its IntelliFill i.v. Automation and IntelliFlowRx Pharmacy Workflow Manager products. The Baxa IntelliSource(TM) program offers health-system pharmacies access to the automation and software they need to ensure that each dose dispensed is safe and accurate - without making capital investments, paying one-time setup fees or signing capital leases.
The Medical Innovation Bill tabled by Lord Saatchi and currently making its way through the UK's House of Lords "strikes at the heart of evidence-based medicine" and risks "opening the door to the use of less proven, or unproven, approaches such as complementary or alternative medicine", according to a new Editorial published in The Lancet Oncology.
Around 20% of breast cancer patients do not complete prescribed endocrine therapy, researchers report at the ESMO Asia 2016 Congress in Singapore.1 The study in over 5,500 women found that younger patients and those who had taken hormone replacement therapy (HRT) were less likely to adhere to their medicine.
NextSource Biotechnology, LLC announced today that Gleostine (lomustine) 5 mg capsules has been approved by the U.S. Food and Drug Administration and is now commercially available in the United States.
› Verified 5 days ago
| Provider Name | Thomas J Guilmette |
|---|---|
| Provider Type | Practitioner - Clinical Psychologist |
| Provider Identifiers | NPI Number: 1629140595 PECOS PAC ID: 3375559107 Enrollment ID: I20060329000117 |
News Archive
Baxa Corporation announces the launch of a new program for sourcing its IntelliFill i.v. Automation and IntelliFlowRx Pharmacy Workflow Manager products. The Baxa IntelliSource(TM) program offers health-system pharmacies access to the automation and software they need to ensure that each dose dispensed is safe and accurate - without making capital investments, paying one-time setup fees or signing capital leases.
The Medical Innovation Bill tabled by Lord Saatchi and currently making its way through the UK's House of Lords "strikes at the heart of evidence-based medicine" and risks "opening the door to the use of less proven, or unproven, approaches such as complementary or alternative medicine", according to a new Editorial published in The Lancet Oncology.
Around 20% of breast cancer patients do not complete prescribed endocrine therapy, researchers report at the ESMO Asia 2016 Congress in Singapore.1 The study in over 5,500 women found that younger patients and those who had taken hormone replacement therapy (HRT) were less likely to adhere to their medicine.
NextSource Biotechnology, LLC announced today that Gleostine (lomustine) 5 mg capsules has been approved by the U.S. Food and Drug Administration and is now commercially available in the United States.
› Verified 5 days ago
| Provider Name | Jeanne Knight |
|---|---|
| Provider Type | Practitioner - Nurse Practitioner |
| Provider Identifiers | NPI Number: 1174588875 PECOS PAC ID: 2466463252 Enrollment ID: I20060508000749 |
News Archive
Baxa Corporation announces the launch of a new program for sourcing its IntelliFill i.v. Automation and IntelliFlowRx Pharmacy Workflow Manager products. The Baxa IntelliSource(TM) program offers health-system pharmacies access to the automation and software they need to ensure that each dose dispensed is safe and accurate - without making capital investments, paying one-time setup fees or signing capital leases.
The Medical Innovation Bill tabled by Lord Saatchi and currently making its way through the UK's House of Lords "strikes at the heart of evidence-based medicine" and risks "opening the door to the use of less proven, or unproven, approaches such as complementary or alternative medicine", according to a new Editorial published in The Lancet Oncology.
Around 20% of breast cancer patients do not complete prescribed endocrine therapy, researchers report at the ESMO Asia 2016 Congress in Singapore.1 The study in over 5,500 women found that younger patients and those who had taken hormone replacement therapy (HRT) were less likely to adhere to their medicine.
NextSource Biotechnology, LLC announced today that Gleostine (lomustine) 5 mg capsules has been approved by the U.S. Food and Drug Administration and is now commercially available in the United States.
› Verified 5 days ago
| Provider Name | Richard D Smith |
|---|---|
| Provider Type | Practitioner - Addiction Medicine |
| Provider Identifiers | NPI Number: 1215993993 PECOS PAC ID: 2860404407 Enrollment ID: I20060622000100 |
News Archive
Baxa Corporation announces the launch of a new program for sourcing its IntelliFill i.v. Automation and IntelliFlowRx Pharmacy Workflow Manager products. The Baxa IntelliSource(TM) program offers health-system pharmacies access to the automation and software they need to ensure that each dose dispensed is safe and accurate - without making capital investments, paying one-time setup fees or signing capital leases.
The Medical Innovation Bill tabled by Lord Saatchi and currently making its way through the UK's House of Lords "strikes at the heart of evidence-based medicine" and risks "opening the door to the use of less proven, or unproven, approaches such as complementary or alternative medicine", according to a new Editorial published in The Lancet Oncology.
Around 20% of breast cancer patients do not complete prescribed endocrine therapy, researchers report at the ESMO Asia 2016 Congress in Singapore.1 The study in over 5,500 women found that younger patients and those who had taken hormone replacement therapy (HRT) were less likely to adhere to their medicine.
NextSource Biotechnology, LLC announced today that Gleostine (lomustine) 5 mg capsules has been approved by the U.S. Food and Drug Administration and is now commercially available in the United States.
› Verified 5 days ago
| Provider Name | Andrew Stone |
|---|---|
| Provider Type | Practitioner - Internal Medicine |
| Provider Identifiers | NPI Number: 1538108857 PECOS PAC ID: 5698778223 Enrollment ID: I20060821000101 |
News Archive
Baxa Corporation announces the launch of a new program for sourcing its IntelliFill i.v. Automation and IntelliFlowRx Pharmacy Workflow Manager products. The Baxa IntelliSource(TM) program offers health-system pharmacies access to the automation and software they need to ensure that each dose dispensed is safe and accurate - without making capital investments, paying one-time setup fees or signing capital leases.
The Medical Innovation Bill tabled by Lord Saatchi and currently making its way through the UK's House of Lords "strikes at the heart of evidence-based medicine" and risks "opening the door to the use of less proven, or unproven, approaches such as complementary or alternative medicine", according to a new Editorial published in The Lancet Oncology.
Around 20% of breast cancer patients do not complete prescribed endocrine therapy, researchers report at the ESMO Asia 2016 Congress in Singapore.1 The study in over 5,500 women found that younger patients and those who had taken hormone replacement therapy (HRT) were less likely to adhere to their medicine.
NextSource Biotechnology, LLC announced today that Gleostine (lomustine) 5 mg capsules has been approved by the U.S. Food and Drug Administration and is now commercially available in the United States.
› Verified 5 days ago
| Provider Name | Allison L Bernier |
|---|---|
| Provider Type | Practitioner - Clinical Social Worker |
| Provider Identifiers | NPI Number: 1053429332 PECOS PAC ID: 4789680778 Enrollment ID: I20061016000115 |
News Archive
Baxa Corporation announces the launch of a new program for sourcing its IntelliFill i.v. Automation and IntelliFlowRx Pharmacy Workflow Manager products. The Baxa IntelliSource(TM) program offers health-system pharmacies access to the automation and software they need to ensure that each dose dispensed is safe and accurate - without making capital investments, paying one-time setup fees or signing capital leases.
The Medical Innovation Bill tabled by Lord Saatchi and currently making its way through the UK's House of Lords "strikes at the heart of evidence-based medicine" and risks "opening the door to the use of less proven, or unproven, approaches such as complementary or alternative medicine", according to a new Editorial published in The Lancet Oncology.
Around 20% of breast cancer patients do not complete prescribed endocrine therapy, researchers report at the ESMO Asia 2016 Congress in Singapore.1 The study in over 5,500 women found that younger patients and those who had taken hormone replacement therapy (HRT) were less likely to adhere to their medicine.
NextSource Biotechnology, LLC announced today that Gleostine (lomustine) 5 mg capsules has been approved by the U.S. Food and Drug Administration and is now commercially available in the United States.
› Verified 5 days ago
| Provider Name | Nebyou Belay |
|---|---|
| Provider Type | Practitioner - Addiction Medicine |
| Provider Identifiers | NPI Number: 1194810507 PECOS PAC ID: 2860491032 Enrollment ID: I20061216000077 |
News Archive
Baxa Corporation announces the launch of a new program for sourcing its IntelliFill i.v. Automation and IntelliFlowRx Pharmacy Workflow Manager products. The Baxa IntelliSource(TM) program offers health-system pharmacies access to the automation and software they need to ensure that each dose dispensed is safe and accurate - without making capital investments, paying one-time setup fees or signing capital leases.
The Medical Innovation Bill tabled by Lord Saatchi and currently making its way through the UK's House of Lords "strikes at the heart of evidence-based medicine" and risks "opening the door to the use of less proven, or unproven, approaches such as complementary or alternative medicine", according to a new Editorial published in The Lancet Oncology.
Around 20% of breast cancer patients do not complete prescribed endocrine therapy, researchers report at the ESMO Asia 2016 Congress in Singapore.1 The study in over 5,500 women found that younger patients and those who had taken hormone replacement therapy (HRT) were less likely to adhere to their medicine.
NextSource Biotechnology, LLC announced today that Gleostine (lomustine) 5 mg capsules has been approved by the U.S. Food and Drug Administration and is now commercially available in the United States.
› Verified 5 days ago
| Provider Name | Kazi M Salahuddin |
|---|---|
| Provider Type | Practitioner - Psychiatry |
| Provider Identifiers | NPI Number: 1558306225 PECOS PAC ID: 0042302952 Enrollment ID: I20070823000440 |
News Archive
Baxa Corporation announces the launch of a new program for sourcing its IntelliFill i.v. Automation and IntelliFlowRx Pharmacy Workflow Manager products. The Baxa IntelliSource(TM) program offers health-system pharmacies access to the automation and software they need to ensure that each dose dispensed is safe and accurate - without making capital investments, paying one-time setup fees or signing capital leases.
The Medical Innovation Bill tabled by Lord Saatchi and currently making its way through the UK's House of Lords "strikes at the heart of evidence-based medicine" and risks "opening the door to the use of less proven, or unproven, approaches such as complementary or alternative medicine", according to a new Editorial published in The Lancet Oncology.
Around 20% of breast cancer patients do not complete prescribed endocrine therapy, researchers report at the ESMO Asia 2016 Congress in Singapore.1 The study in over 5,500 women found that younger patients and those who had taken hormone replacement therapy (HRT) were less likely to adhere to their medicine.
NextSource Biotechnology, LLC announced today that Gleostine (lomustine) 5 mg capsules has been approved by the U.S. Food and Drug Administration and is now commercially available in the United States.
› Verified 5 days ago
| Provider Name | Scott Haltzman |
|---|---|
| Provider Type | Practitioner - Psychiatry |
| Provider Identifiers | NPI Number: 1922025766 PECOS PAC ID: 0042221046 Enrollment ID: I20071107000618 |
News Archive
Baxa Corporation announces the launch of a new program for sourcing its IntelliFill i.v. Automation and IntelliFlowRx Pharmacy Workflow Manager products. The Baxa IntelliSource(TM) program offers health-system pharmacies access to the automation and software they need to ensure that each dose dispensed is safe and accurate - without making capital investments, paying one-time setup fees or signing capital leases.
The Medical Innovation Bill tabled by Lord Saatchi and currently making its way through the UK's House of Lords "strikes at the heart of evidence-based medicine" and risks "opening the door to the use of less proven, or unproven, approaches such as complementary or alternative medicine", according to a new Editorial published in The Lancet Oncology.
Around 20% of breast cancer patients do not complete prescribed endocrine therapy, researchers report at the ESMO Asia 2016 Congress in Singapore.1 The study in over 5,500 women found that younger patients and those who had taken hormone replacement therapy (HRT) were less likely to adhere to their medicine.
NextSource Biotechnology, LLC announced today that Gleostine (lomustine) 5 mg capsules has been approved by the U.S. Food and Drug Administration and is now commercially available in the United States.
› Verified 5 days ago
| Provider Name | Dale L Folan |
|---|---|
| Provider Type | Practitioner - Clinical Social Worker |
| Provider Identifiers | NPI Number: 1619162286 PECOS PAC ID: 5496843591 Enrollment ID: I20071126000354 |
News Archive
Baxa Corporation announces the launch of a new program for sourcing its IntelliFill i.v. Automation and IntelliFlowRx Pharmacy Workflow Manager products. The Baxa IntelliSource(TM) program offers health-system pharmacies access to the automation and software they need to ensure that each dose dispensed is safe and accurate - without making capital investments, paying one-time setup fees or signing capital leases.
The Medical Innovation Bill tabled by Lord Saatchi and currently making its way through the UK's House of Lords "strikes at the heart of evidence-based medicine" and risks "opening the door to the use of less proven, or unproven, approaches such as complementary or alternative medicine", according to a new Editorial published in The Lancet Oncology.
Around 20% of breast cancer patients do not complete prescribed endocrine therapy, researchers report at the ESMO Asia 2016 Congress in Singapore.1 The study in over 5,500 women found that younger patients and those who had taken hormone replacement therapy (HRT) were less likely to adhere to their medicine.
NextSource Biotechnology, LLC announced today that Gleostine (lomustine) 5 mg capsules has been approved by the U.S. Food and Drug Administration and is now commercially available in the United States.
› Verified 5 days ago
| Provider Name | Neenoofar Haneef |
|---|---|
| Provider Type | Practitioner - Internal Medicine |
| Provider Identifiers | NPI Number: 1871772160 PECOS PAC ID: 4789767401 Enrollment ID: I20080218000653 |
News Archive
Baxa Corporation announces the launch of a new program for sourcing its IntelliFill i.v. Automation and IntelliFlowRx Pharmacy Workflow Manager products. The Baxa IntelliSource(TM) program offers health-system pharmacies access to the automation and software they need to ensure that each dose dispensed is safe and accurate - without making capital investments, paying one-time setup fees or signing capital leases.
The Medical Innovation Bill tabled by Lord Saatchi and currently making its way through the UK's House of Lords "strikes at the heart of evidence-based medicine" and risks "opening the door to the use of less proven, or unproven, approaches such as complementary or alternative medicine", according to a new Editorial published in The Lancet Oncology.
Around 20% of breast cancer patients do not complete prescribed endocrine therapy, researchers report at the ESMO Asia 2016 Congress in Singapore.1 The study in over 5,500 women found that younger patients and those who had taken hormone replacement therapy (HRT) were less likely to adhere to their medicine.
NextSource Biotechnology, LLC announced today that Gleostine (lomustine) 5 mg capsules has been approved by the U.S. Food and Drug Administration and is now commercially available in the United States.
› Verified 5 days ago
| Provider Name | Andrew John Lemoi |
|---|---|
| Provider Type | Practitioner - Podiatry |
| Provider Identifiers | NPI Number: 1114912193 PECOS PAC ID: 2466538178 Enrollment ID: I20080320000488 |
News Archive
Baxa Corporation announces the launch of a new program for sourcing its IntelliFill i.v. Automation and IntelliFlowRx Pharmacy Workflow Manager products. The Baxa IntelliSource(TM) program offers health-system pharmacies access to the automation and software they need to ensure that each dose dispensed is safe and accurate - without making capital investments, paying one-time setup fees or signing capital leases.
The Medical Innovation Bill tabled by Lord Saatchi and currently making its way through the UK's House of Lords "strikes at the heart of evidence-based medicine" and risks "opening the door to the use of less proven, or unproven, approaches such as complementary or alternative medicine", according to a new Editorial published in The Lancet Oncology.
Around 20% of breast cancer patients do not complete prescribed endocrine therapy, researchers report at the ESMO Asia 2016 Congress in Singapore.1 The study in over 5,500 women found that younger patients and those who had taken hormone replacement therapy (HRT) were less likely to adhere to their medicine.
NextSource Biotechnology, LLC announced today that Gleostine (lomustine) 5 mg capsules has been approved by the U.S. Food and Drug Administration and is now commercially available in the United States.
› Verified 5 days ago
| Provider Name | Jon A Mukand |
|---|---|
| Provider Type | Practitioner - Physical Medicine And Rehabilitation |
| Provider Identifiers | NPI Number: 1083787816 PECOS PAC ID: 3577581495 Enrollment ID: I20080325000638 |
News Archive
Baxa Corporation announces the launch of a new program for sourcing its IntelliFill i.v. Automation and IntelliFlowRx Pharmacy Workflow Manager products. The Baxa IntelliSource(TM) program offers health-system pharmacies access to the automation and software they need to ensure that each dose dispensed is safe and accurate - without making capital investments, paying one-time setup fees or signing capital leases.
The Medical Innovation Bill tabled by Lord Saatchi and currently making its way through the UK's House of Lords "strikes at the heart of evidence-based medicine" and risks "opening the door to the use of less proven, or unproven, approaches such as complementary or alternative medicine", according to a new Editorial published in The Lancet Oncology.
Around 20% of breast cancer patients do not complete prescribed endocrine therapy, researchers report at the ESMO Asia 2016 Congress in Singapore.1 The study in over 5,500 women found that younger patients and those who had taken hormone replacement therapy (HRT) were less likely to adhere to their medicine.
NextSource Biotechnology, LLC announced today that Gleostine (lomustine) 5 mg capsules has been approved by the U.S. Food and Drug Administration and is now commercially available in the United States.
› Verified 5 days ago
| Provider Name | Barbara J Forloney |
|---|---|
| Provider Type | Practitioner - Certified Clinical Nurse Specialist (cns) |
| Provider Identifiers | NPI Number: 1215108717 PECOS PAC ID: 8325111628 Enrollment ID: I20080721000101 |
News Archive
Baxa Corporation announces the launch of a new program for sourcing its IntelliFill i.v. Automation and IntelliFlowRx Pharmacy Workflow Manager products. The Baxa IntelliSource(TM) program offers health-system pharmacies access to the automation and software they need to ensure that each dose dispensed is safe and accurate - without making capital investments, paying one-time setup fees or signing capital leases.
The Medical Innovation Bill tabled by Lord Saatchi and currently making its way through the UK's House of Lords "strikes at the heart of evidence-based medicine" and risks "opening the door to the use of less proven, or unproven, approaches such as complementary or alternative medicine", according to a new Editorial published in The Lancet Oncology.
Around 20% of breast cancer patients do not complete prescribed endocrine therapy, researchers report at the ESMO Asia 2016 Congress in Singapore.1 The study in over 5,500 women found that younger patients and those who had taken hormone replacement therapy (HRT) were less likely to adhere to their medicine.
NextSource Biotechnology, LLC announced today that Gleostine (lomustine) 5 mg capsules has been approved by the U.S. Food and Drug Administration and is now commercially available in the United States.
› Verified 5 days ago
| Provider Name | Amy Laura Snyder |
|---|---|
| Provider Type | Practitioner - Obstetrics/gynecology |
| Provider Identifiers | NPI Number: 1265535355 PECOS PAC ID: 0648347765 Enrollment ID: I20080916000015 |
News Archive
Baxa Corporation announces the launch of a new program for sourcing its IntelliFill i.v. Automation and IntelliFlowRx Pharmacy Workflow Manager products. The Baxa IntelliSource(TM) program offers health-system pharmacies access to the automation and software they need to ensure that each dose dispensed is safe and accurate - without making capital investments, paying one-time setup fees or signing capital leases.
The Medical Innovation Bill tabled by Lord Saatchi and currently making its way through the UK's House of Lords "strikes at the heart of evidence-based medicine" and risks "opening the door to the use of less proven, or unproven, approaches such as complementary or alternative medicine", according to a new Editorial published in The Lancet Oncology.
Around 20% of breast cancer patients do not complete prescribed endocrine therapy, researchers report at the ESMO Asia 2016 Congress in Singapore.1 The study in over 5,500 women found that younger patients and those who had taken hormone replacement therapy (HRT) were less likely to adhere to their medicine.
NextSource Biotechnology, LLC announced today that Gleostine (lomustine) 5 mg capsules has been approved by the U.S. Food and Drug Administration and is now commercially available in the United States.
› Verified 5 days ago
| Provider Name | Peter M Small |
|---|---|
| Provider Type | Practitioner - Family Practice |
| Provider Identifiers | NPI Number: 1972557346 PECOS PAC ID: 0042379455 Enrollment ID: I20081030000037 |
News Archive
Baxa Corporation announces the launch of a new program for sourcing its IntelliFill i.v. Automation and IntelliFlowRx Pharmacy Workflow Manager products. The Baxa IntelliSource(TM) program offers health-system pharmacies access to the automation and software they need to ensure that each dose dispensed is safe and accurate - without making capital investments, paying one-time setup fees or signing capital leases.
The Medical Innovation Bill tabled by Lord Saatchi and currently making its way through the UK's House of Lords "strikes at the heart of evidence-based medicine" and risks "opening the door to the use of less proven, or unproven, approaches such as complementary or alternative medicine", according to a new Editorial published in The Lancet Oncology.
Around 20% of breast cancer patients do not complete prescribed endocrine therapy, researchers report at the ESMO Asia 2016 Congress in Singapore.1 The study in over 5,500 women found that younger patients and those who had taken hormone replacement therapy (HRT) were less likely to adhere to their medicine.
NextSource Biotechnology, LLC announced today that Gleostine (lomustine) 5 mg capsules has been approved by the U.S. Food and Drug Administration and is now commercially available in the United States.
› Verified 5 days ago
| Provider Name | Gerald Marsocci |
|---|---|
| Provider Type | Practitioner - General Surgery |
| Provider Identifiers | NPI Number: 1386649523 PECOS PAC ID: 7416016720 Enrollment ID: I20081031000229 |
News Archive
Baxa Corporation announces the launch of a new program for sourcing its IntelliFill i.v. Automation and IntelliFlowRx Pharmacy Workflow Manager products. The Baxa IntelliSource(TM) program offers health-system pharmacies access to the automation and software they need to ensure that each dose dispensed is safe and accurate - without making capital investments, paying one-time setup fees or signing capital leases.
The Medical Innovation Bill tabled by Lord Saatchi and currently making its way through the UK's House of Lords "strikes at the heart of evidence-based medicine" and risks "opening the door to the use of less proven, or unproven, approaches such as complementary or alternative medicine", according to a new Editorial published in The Lancet Oncology.
Around 20% of breast cancer patients do not complete prescribed endocrine therapy, researchers report at the ESMO Asia 2016 Congress in Singapore.1 The study in over 5,500 women found that younger patients and those who had taken hormone replacement therapy (HRT) were less likely to adhere to their medicine.
NextSource Biotechnology, LLC announced today that Gleostine (lomustine) 5 mg capsules has been approved by the U.S. Food and Drug Administration and is now commercially available in the United States.
› Verified 5 days ago
| Provider Name | Mark A Shannon |
|---|---|
| Provider Type | Practitioner - Internal Medicine |
| Provider Identifiers | NPI Number: 1508941089 PECOS PAC ID: 7517026099 Enrollment ID: I20081113000039 |
News Archive
Baxa Corporation announces the launch of a new program for sourcing its IntelliFill i.v. Automation and IntelliFlowRx Pharmacy Workflow Manager products. The Baxa IntelliSource(TM) program offers health-system pharmacies access to the automation and software they need to ensure that each dose dispensed is safe and accurate - without making capital investments, paying one-time setup fees or signing capital leases.
The Medical Innovation Bill tabled by Lord Saatchi and currently making its way through the UK's House of Lords "strikes at the heart of evidence-based medicine" and risks "opening the door to the use of less proven, or unproven, approaches such as complementary or alternative medicine", according to a new Editorial published in The Lancet Oncology.
Around 20% of breast cancer patients do not complete prescribed endocrine therapy, researchers report at the ESMO Asia 2016 Congress in Singapore.1 The study in over 5,500 women found that younger patients and those who had taken hormone replacement therapy (HRT) were less likely to adhere to their medicine.
NextSource Biotechnology, LLC announced today that Gleostine (lomustine) 5 mg capsules has been approved by the U.S. Food and Drug Administration and is now commercially available in the United States.
› Verified 5 days ago
| Provider Name | Deborah E Carranza |
|---|---|
| Provider Type | Practitioner - Clinical Social Worker |
| Provider Identifiers | NPI Number: 1700119062 PECOS PAC ID: 1153460548 Enrollment ID: I20091124000346 |
News Archive
Baxa Corporation announces the launch of a new program for sourcing its IntelliFill i.v. Automation and IntelliFlowRx Pharmacy Workflow Manager products. The Baxa IntelliSource(TM) program offers health-system pharmacies access to the automation and software they need to ensure that each dose dispensed is safe and accurate - without making capital investments, paying one-time setup fees or signing capital leases.
The Medical Innovation Bill tabled by Lord Saatchi and currently making its way through the UK's House of Lords "strikes at the heart of evidence-based medicine" and risks "opening the door to the use of less proven, or unproven, approaches such as complementary or alternative medicine", according to a new Editorial published in The Lancet Oncology.
Around 20% of breast cancer patients do not complete prescribed endocrine therapy, researchers report at the ESMO Asia 2016 Congress in Singapore.1 The study in over 5,500 women found that younger patients and those who had taken hormone replacement therapy (HRT) were less likely to adhere to their medicine.
NextSource Biotechnology, LLC announced today that Gleostine (lomustine) 5 mg capsules has been approved by the U.S. Food and Drug Administration and is now commercially available in the United States.
› Verified 5 days ago
| Provider Name | Elizabeth Conklin |
|---|---|
| Provider Type | Practitioner - General Surgery |
| Provider Identifiers | NPI Number: 1649359704 PECOS PAC ID: 8628158532 Enrollment ID: I20100113000309 |
News Archive
Baxa Corporation announces the launch of a new program for sourcing its IntelliFill i.v. Automation and IntelliFlowRx Pharmacy Workflow Manager products. The Baxa IntelliSource(TM) program offers health-system pharmacies access to the automation and software they need to ensure that each dose dispensed is safe and accurate - without making capital investments, paying one-time setup fees or signing capital leases.
The Medical Innovation Bill tabled by Lord Saatchi and currently making its way through the UK's House of Lords "strikes at the heart of evidence-based medicine" and risks "opening the door to the use of less proven, or unproven, approaches such as complementary or alternative medicine", according to a new Editorial published in The Lancet Oncology.
Around 20% of breast cancer patients do not complete prescribed endocrine therapy, researchers report at the ESMO Asia 2016 Congress in Singapore.1 The study in over 5,500 women found that younger patients and those who had taken hormone replacement therapy (HRT) were less likely to adhere to their medicine.
NextSource Biotechnology, LLC announced today that Gleostine (lomustine) 5 mg capsules has been approved by the U.S. Food and Drug Administration and is now commercially available in the United States.
› Verified 5 days ago
| Provider Name | Joseph K Domenico |
|---|---|
| Provider Type | Practitioner - Podiatry |
| Provider Identifiers | NPI Number: 1972780583 PECOS PAC ID: 9436291002 Enrollment ID: I20100120000118 |
News Archive
Baxa Corporation announces the launch of a new program for sourcing its IntelliFill i.v. Automation and IntelliFlowRx Pharmacy Workflow Manager products. The Baxa IntelliSource(TM) program offers health-system pharmacies access to the automation and software they need to ensure that each dose dispensed is safe and accurate - without making capital investments, paying one-time setup fees or signing capital leases.
The Medical Innovation Bill tabled by Lord Saatchi and currently making its way through the UK's House of Lords "strikes at the heart of evidence-based medicine" and risks "opening the door to the use of less proven, or unproven, approaches such as complementary or alternative medicine", according to a new Editorial published in The Lancet Oncology.
Around 20% of breast cancer patients do not complete prescribed endocrine therapy, researchers report at the ESMO Asia 2016 Congress in Singapore.1 The study in over 5,500 women found that younger patients and those who had taken hormone replacement therapy (HRT) were less likely to adhere to their medicine.
NextSource Biotechnology, LLC announced today that Gleostine (lomustine) 5 mg capsules has been approved by the U.S. Food and Drug Administration and is now commercially available in the United States.
› Verified 5 days ago
| Provider Name | Scott E Mcdonald |
|---|---|
| Provider Type | Practitioner - Psychiatry |
| Provider Identifiers | NPI Number: 1942239363 PECOS PAC ID: 5193618130 Enrollment ID: I20100126000562 |
News Archive
Baxa Corporation announces the launch of a new program for sourcing its IntelliFill i.v. Automation and IntelliFlowRx Pharmacy Workflow Manager products. The Baxa IntelliSource(TM) program offers health-system pharmacies access to the automation and software they need to ensure that each dose dispensed is safe and accurate - without making capital investments, paying one-time setup fees or signing capital leases.
The Medical Innovation Bill tabled by Lord Saatchi and currently making its way through the UK's House of Lords "strikes at the heart of evidence-based medicine" and risks "opening the door to the use of less proven, or unproven, approaches such as complementary or alternative medicine", according to a new Editorial published in The Lancet Oncology.
Around 20% of breast cancer patients do not complete prescribed endocrine therapy, researchers report at the ESMO Asia 2016 Congress in Singapore.1 The study in over 5,500 women found that younger patients and those who had taken hormone replacement therapy (HRT) were less likely to adhere to their medicine.
NextSource Biotechnology, LLC announced today that Gleostine (lomustine) 5 mg capsules has been approved by the U.S. Food and Drug Administration and is now commercially available in the United States.
› Verified 5 days ago
| Provider Name | Joseph J Doerr |
|---|---|
| Provider Type | Practitioner - Physical Medicine And Rehabilitation |
| Provider Identifiers | NPI Number: 1427052703 PECOS PAC ID: 7810939386 Enrollment ID: I20100319000527 |
News Archive
Baxa Corporation announces the launch of a new program for sourcing its IntelliFill i.v. Automation and IntelliFlowRx Pharmacy Workflow Manager products. The Baxa IntelliSource(TM) program offers health-system pharmacies access to the automation and software they need to ensure that each dose dispensed is safe and accurate - without making capital investments, paying one-time setup fees or signing capital leases.
The Medical Innovation Bill tabled by Lord Saatchi and currently making its way through the UK's House of Lords "strikes at the heart of evidence-based medicine" and risks "opening the door to the use of less proven, or unproven, approaches such as complementary or alternative medicine", according to a new Editorial published in The Lancet Oncology.
Around 20% of breast cancer patients do not complete prescribed endocrine therapy, researchers report at the ESMO Asia 2016 Congress in Singapore.1 The study in over 5,500 women found that younger patients and those who had taken hormone replacement therapy (HRT) were less likely to adhere to their medicine.
NextSource Biotechnology, LLC announced today that Gleostine (lomustine) 5 mg capsules has been approved by the U.S. Food and Drug Administration and is now commercially available in the United States.
› Verified 5 days ago
| Provider Name | William E Ottowitz |
|---|---|
| Provider Type | Practitioner - Psychiatry |
| Provider Identifiers | NPI Number: 1932205655 PECOS PAC ID: 1456480334 Enrollment ID: I20100602000865 |
News Archive
Baxa Corporation announces the launch of a new program for sourcing its IntelliFill i.v. Automation and IntelliFlowRx Pharmacy Workflow Manager products. The Baxa IntelliSource(TM) program offers health-system pharmacies access to the automation and software they need to ensure that each dose dispensed is safe and accurate - without making capital investments, paying one-time setup fees or signing capital leases.
The Medical Innovation Bill tabled by Lord Saatchi and currently making its way through the UK's House of Lords "strikes at the heart of evidence-based medicine" and risks "opening the door to the use of less proven, or unproven, approaches such as complementary or alternative medicine", according to a new Editorial published in The Lancet Oncology.
Around 20% of breast cancer patients do not complete prescribed endocrine therapy, researchers report at the ESMO Asia 2016 Congress in Singapore.1 The study in over 5,500 women found that younger patients and those who had taken hormone replacement therapy (HRT) were less likely to adhere to their medicine.
NextSource Biotechnology, LLC announced today that Gleostine (lomustine) 5 mg capsules has been approved by the U.S. Food and Drug Administration and is now commercially available in the United States.
› Verified 5 days ago
| Provider Name | Jeiny Zapata |
|---|---|
| Provider Type | Practitioner - Nurse Practitioner |
| Provider Identifiers | NPI Number: 1750548665 PECOS PAC ID: 4981888450 Enrollment ID: I20110407000026 |
News Archive
Baxa Corporation announces the launch of a new program for sourcing its IntelliFill i.v. Automation and IntelliFlowRx Pharmacy Workflow Manager products. The Baxa IntelliSource(TM) program offers health-system pharmacies access to the automation and software they need to ensure that each dose dispensed is safe and accurate - without making capital investments, paying one-time setup fees or signing capital leases.
The Medical Innovation Bill tabled by Lord Saatchi and currently making its way through the UK's House of Lords "strikes at the heart of evidence-based medicine" and risks "opening the door to the use of less proven, or unproven, approaches such as complementary or alternative medicine", according to a new Editorial published in The Lancet Oncology.
Around 20% of breast cancer patients do not complete prescribed endocrine therapy, researchers report at the ESMO Asia 2016 Congress in Singapore.1 The study in over 5,500 women found that younger patients and those who had taken hormone replacement therapy (HRT) were less likely to adhere to their medicine.
NextSource Biotechnology, LLC announced today that Gleostine (lomustine) 5 mg capsules has been approved by the U.S. Food and Drug Administration and is now commercially available in the United States.
› Verified 5 days ago
| Provider Name | Michael D Burgard |
|---|---|
| Provider Type | Practitioner - Psychiatry |
| Provider Identifiers | NPI Number: 1346458205 PECOS PAC ID: 7012181910 Enrollment ID: I20111110000361 |
News Archive
Baxa Corporation announces the launch of a new program for sourcing its IntelliFill i.v. Automation and IntelliFlowRx Pharmacy Workflow Manager products. The Baxa IntelliSource(TM) program offers health-system pharmacies access to the automation and software they need to ensure that each dose dispensed is safe and accurate - without making capital investments, paying one-time setup fees or signing capital leases.
The Medical Innovation Bill tabled by Lord Saatchi and currently making its way through the UK's House of Lords "strikes at the heart of evidence-based medicine" and risks "opening the door to the use of less proven, or unproven, approaches such as complementary or alternative medicine", according to a new Editorial published in The Lancet Oncology.
Around 20% of breast cancer patients do not complete prescribed endocrine therapy, researchers report at the ESMO Asia 2016 Congress in Singapore.1 The study in over 5,500 women found that younger patients and those who had taken hormone replacement therapy (HRT) were less likely to adhere to their medicine.
NextSource Biotechnology, LLC announced today that Gleostine (lomustine) 5 mg capsules has been approved by the U.S. Food and Drug Administration and is now commercially available in the United States.
› Verified 5 days ago
| Provider Name | Richard William Miller |
|---|---|
| Provider Type | Practitioner - Psychiatry |
| Provider Identifiers | NPI Number: 1114122595 PECOS PAC ID: 9830364041 Enrollment ID: I20111215000669 |
News Archive
Baxa Corporation announces the launch of a new program for sourcing its IntelliFill i.v. Automation and IntelliFlowRx Pharmacy Workflow Manager products. The Baxa IntelliSource(TM) program offers health-system pharmacies access to the automation and software they need to ensure that each dose dispensed is safe and accurate - without making capital investments, paying one-time setup fees or signing capital leases.
The Medical Innovation Bill tabled by Lord Saatchi and currently making its way through the UK's House of Lords "strikes at the heart of evidence-based medicine" and risks "opening the door to the use of less proven, or unproven, approaches such as complementary or alternative medicine", according to a new Editorial published in The Lancet Oncology.
Around 20% of breast cancer patients do not complete prescribed endocrine therapy, researchers report at the ESMO Asia 2016 Congress in Singapore.1 The study in over 5,500 women found that younger patients and those who had taken hormone replacement therapy (HRT) were less likely to adhere to their medicine.
NextSource Biotechnology, LLC announced today that Gleostine (lomustine) 5 mg capsules has been approved by the U.S. Food and Drug Administration and is now commercially available in the United States.
› Verified 5 days ago
| Provider Name | Jeanne M Smith |
|---|---|
| Provider Type | Practitioner - Clinical Social Worker |
| Provider Identifiers | NPI Number: 1710121314 PECOS PAC ID: 5698925220 Enrollment ID: I20121017000356 |
News Archive
Baxa Corporation announces the launch of a new program for sourcing its IntelliFill i.v. Automation and IntelliFlowRx Pharmacy Workflow Manager products. The Baxa IntelliSource(TM) program offers health-system pharmacies access to the automation and software they need to ensure that each dose dispensed is safe and accurate - without making capital investments, paying one-time setup fees or signing capital leases.
The Medical Innovation Bill tabled by Lord Saatchi and currently making its way through the UK's House of Lords "strikes at the heart of evidence-based medicine" and risks "opening the door to the use of less proven, or unproven, approaches such as complementary or alternative medicine", according to a new Editorial published in The Lancet Oncology.
Around 20% of breast cancer patients do not complete prescribed endocrine therapy, researchers report at the ESMO Asia 2016 Congress in Singapore.1 The study in over 5,500 women found that younger patients and those who had taken hormone replacement therapy (HRT) were less likely to adhere to their medicine.
NextSource Biotechnology, LLC announced today that Gleostine (lomustine) 5 mg capsules has been approved by the U.S. Food and Drug Administration and is now commercially available in the United States.
› Verified 5 days ago
| Provider Name | John K Findley |
|---|---|
| Provider Type | Practitioner - Psychiatry |
| Provider Identifiers | NPI Number: 1891777504 PECOS PAC ID: 8628052776 Enrollment ID: I20121018000516 |
News Archive
Baxa Corporation announces the launch of a new program for sourcing its IntelliFill i.v. Automation and IntelliFlowRx Pharmacy Workflow Manager products. The Baxa IntelliSource(TM) program offers health-system pharmacies access to the automation and software they need to ensure that each dose dispensed is safe and accurate - without making capital investments, paying one-time setup fees or signing capital leases.
The Medical Innovation Bill tabled by Lord Saatchi and currently making its way through the UK's House of Lords "strikes at the heart of evidence-based medicine" and risks "opening the door to the use of less proven, or unproven, approaches such as complementary or alternative medicine", according to a new Editorial published in The Lancet Oncology.
Around 20% of breast cancer patients do not complete prescribed endocrine therapy, researchers report at the ESMO Asia 2016 Congress in Singapore.1 The study in over 5,500 women found that younger patients and those who had taken hormone replacement therapy (HRT) were less likely to adhere to their medicine.
NextSource Biotechnology, LLC announced today that Gleostine (lomustine) 5 mg capsules has been approved by the U.S. Food and Drug Administration and is now commercially available in the United States.
› Verified 5 days ago
| Provider Name | Robin A Chiang |
|---|---|
| Provider Type | Practitioner - Clinical Social Worker |
| Provider Identifiers | NPI Number: 1780929026 PECOS PAC ID: 9335394188 Enrollment ID: I20130227000296 |
News Archive
Baxa Corporation announces the launch of a new program for sourcing its IntelliFill i.v. Automation and IntelliFlowRx Pharmacy Workflow Manager products. The Baxa IntelliSource(TM) program offers health-system pharmacies access to the automation and software they need to ensure that each dose dispensed is safe and accurate - without making capital investments, paying one-time setup fees or signing capital leases.
The Medical Innovation Bill tabled by Lord Saatchi and currently making its way through the UK's House of Lords "strikes at the heart of evidence-based medicine" and risks "opening the door to the use of less proven, or unproven, approaches such as complementary or alternative medicine", according to a new Editorial published in The Lancet Oncology.
Around 20% of breast cancer patients do not complete prescribed endocrine therapy, researchers report at the ESMO Asia 2016 Congress in Singapore.1 The study in over 5,500 women found that younger patients and those who had taken hormone replacement therapy (HRT) were less likely to adhere to their medicine.
NextSource Biotechnology, LLC announced today that Gleostine (lomustine) 5 mg capsules has been approved by the U.S. Food and Drug Administration and is now commercially available in the United States.
› Verified 5 days ago
| Provider Name | Aleksandra S Phillips |
|---|---|
| Provider Type | Practitioner - Psychiatry |
| Provider Identifiers | NPI Number: 1316018450 PECOS PAC ID: 7012969439 Enrollment ID: I20130731000274 |
News Archive
Baxa Corporation announces the launch of a new program for sourcing its IntelliFill i.v. Automation and IntelliFlowRx Pharmacy Workflow Manager products. The Baxa IntelliSource(TM) program offers health-system pharmacies access to the automation and software they need to ensure that each dose dispensed is safe and accurate - without making capital investments, paying one-time setup fees or signing capital leases.
The Medical Innovation Bill tabled by Lord Saatchi and currently making its way through the UK's House of Lords "strikes at the heart of evidence-based medicine" and risks "opening the door to the use of less proven, or unproven, approaches such as complementary or alternative medicine", according to a new Editorial published in The Lancet Oncology.
Around 20% of breast cancer patients do not complete prescribed endocrine therapy, researchers report at the ESMO Asia 2016 Congress in Singapore.1 The study in over 5,500 women found that younger patients and those who had taken hormone replacement therapy (HRT) were less likely to adhere to their medicine.
NextSource Biotechnology, LLC announced today that Gleostine (lomustine) 5 mg capsules has been approved by the U.S. Food and Drug Administration and is now commercially available in the United States.
› Verified 5 days ago
| Provider Name | Teresa M Maine |
|---|---|
| Provider Type | Practitioner - Nurse Practitioner |
| Provider Identifiers | NPI Number: 1801237235 PECOS PAC ID: 9638312879 Enrollment ID: I20130906000771 |
News Archive
Baxa Corporation announces the launch of a new program for sourcing its IntelliFill i.v. Automation and IntelliFlowRx Pharmacy Workflow Manager products. The Baxa IntelliSource(TM) program offers health-system pharmacies access to the automation and software they need to ensure that each dose dispensed is safe and accurate - without making capital investments, paying one-time setup fees or signing capital leases.
The Medical Innovation Bill tabled by Lord Saatchi and currently making its way through the UK's House of Lords "strikes at the heart of evidence-based medicine" and risks "opening the door to the use of less proven, or unproven, approaches such as complementary or alternative medicine", according to a new Editorial published in The Lancet Oncology.
Around 20% of breast cancer patients do not complete prescribed endocrine therapy, researchers report at the ESMO Asia 2016 Congress in Singapore.1 The study in over 5,500 women found that younger patients and those who had taken hormone replacement therapy (HRT) were less likely to adhere to their medicine.
NextSource Biotechnology, LLC announced today that Gleostine (lomustine) 5 mg capsules has been approved by the U.S. Food and Drug Administration and is now commercially available in the United States.
› Verified 5 days ago
| Provider Name | Jesus Sosa |
|---|---|
| Provider Type | Practitioner - Family Practice |
| Provider Identifiers | NPI Number: 1508850975 PECOS PAC ID: 0446298517 Enrollment ID: I20131115001153 |
News Archive
Baxa Corporation announces the launch of a new program for sourcing its IntelliFill i.v. Automation and IntelliFlowRx Pharmacy Workflow Manager products. The Baxa IntelliSource(TM) program offers health-system pharmacies access to the automation and software they need to ensure that each dose dispensed is safe and accurate - without making capital investments, paying one-time setup fees or signing capital leases.
The Medical Innovation Bill tabled by Lord Saatchi and currently making its way through the UK's House of Lords "strikes at the heart of evidence-based medicine" and risks "opening the door to the use of less proven, or unproven, approaches such as complementary or alternative medicine", according to a new Editorial published in The Lancet Oncology.
Around 20% of breast cancer patients do not complete prescribed endocrine therapy, researchers report at the ESMO Asia 2016 Congress in Singapore.1 The study in over 5,500 women found that younger patients and those who had taken hormone replacement therapy (HRT) were less likely to adhere to their medicine.
NextSource Biotechnology, LLC announced today that Gleostine (lomustine) 5 mg capsules has been approved by the U.S. Food and Drug Administration and is now commercially available in the United States.
› Verified 5 days ago
| Provider Name | Khin Sein Yin |
|---|---|
| Provider Type | Practitioner - Physical Medicine And Rehabilitation |
| Provider Identifiers | NPI Number: 1073537585 PECOS PAC ID: 1456354828 Enrollment ID: I20140227000187 |
News Archive
Baxa Corporation announces the launch of a new program for sourcing its IntelliFill i.v. Automation and IntelliFlowRx Pharmacy Workflow Manager products. The Baxa IntelliSource(TM) program offers health-system pharmacies access to the automation and software they need to ensure that each dose dispensed is safe and accurate - without making capital investments, paying one-time setup fees or signing capital leases.
The Medical Innovation Bill tabled by Lord Saatchi and currently making its way through the UK's House of Lords "strikes at the heart of evidence-based medicine" and risks "opening the door to the use of less proven, or unproven, approaches such as complementary or alternative medicine", according to a new Editorial published in The Lancet Oncology.
Around 20% of breast cancer patients do not complete prescribed endocrine therapy, researchers report at the ESMO Asia 2016 Congress in Singapore.1 The study in over 5,500 women found that younger patients and those who had taken hormone replacement therapy (HRT) were less likely to adhere to their medicine.
NextSource Biotechnology, LLC announced today that Gleostine (lomustine) 5 mg capsules has been approved by the U.S. Food and Drug Administration and is now commercially available in the United States.
› Verified 5 days ago
| Provider Name | Kate M Zaluski |
|---|---|
| Provider Type | Practitioner - Obstetrics/gynecology |
| Provider Identifiers | NPI Number: 1558599464 PECOS PAC ID: 4688805831 Enrollment ID: I20140401001278 |
News Archive
Baxa Corporation announces the launch of a new program for sourcing its IntelliFill i.v. Automation and IntelliFlowRx Pharmacy Workflow Manager products. The Baxa IntelliSource(TM) program offers health-system pharmacies access to the automation and software they need to ensure that each dose dispensed is safe and accurate - without making capital investments, paying one-time setup fees or signing capital leases.
The Medical Innovation Bill tabled by Lord Saatchi and currently making its way through the UK's House of Lords "strikes at the heart of evidence-based medicine" and risks "opening the door to the use of less proven, or unproven, approaches such as complementary or alternative medicine", according to a new Editorial published in The Lancet Oncology.
Around 20% of breast cancer patients do not complete prescribed endocrine therapy, researchers report at the ESMO Asia 2016 Congress in Singapore.1 The study in over 5,500 women found that younger patients and those who had taken hormone replacement therapy (HRT) were less likely to adhere to their medicine.
NextSource Biotechnology, LLC announced today that Gleostine (lomustine) 5 mg capsules has been approved by the U.S. Food and Drug Administration and is now commercially available in the United States.
› Verified 5 days ago
| Provider Name | Laura M Linback |
|---|---|
| Provider Type | Practitioner - Clinical Social Worker |
| Provider Identifiers | NPI Number: 1124294087 PECOS PAC ID: 9739311226 Enrollment ID: I20140416000536 |
News Archive
Baxa Corporation announces the launch of a new program for sourcing its IntelliFill i.v. Automation and IntelliFlowRx Pharmacy Workflow Manager products. The Baxa IntelliSource(TM) program offers health-system pharmacies access to the automation and software they need to ensure that each dose dispensed is safe and accurate - without making capital investments, paying one-time setup fees or signing capital leases.
The Medical Innovation Bill tabled by Lord Saatchi and currently making its way through the UK's House of Lords "strikes at the heart of evidence-based medicine" and risks "opening the door to the use of less proven, or unproven, approaches such as complementary or alternative medicine", according to a new Editorial published in The Lancet Oncology.
Around 20% of breast cancer patients do not complete prescribed endocrine therapy, researchers report at the ESMO Asia 2016 Congress in Singapore.1 The study in over 5,500 women found that younger patients and those who had taken hormone replacement therapy (HRT) were less likely to adhere to their medicine.
NextSource Biotechnology, LLC announced today that Gleostine (lomustine) 5 mg capsules has been approved by the U.S. Food and Drug Administration and is now commercially available in the United States.
› Verified 5 days ago
| Provider Name | Jessica Lima Garcia |
|---|---|
| Provider Type | Practitioner - Clinical Social Worker |
| Provider Identifiers | NPI Number: 1699014423 PECOS PAC ID: 8325261837 Enrollment ID: I20140529002414 |
News Archive
Baxa Corporation announces the launch of a new program for sourcing its IntelliFill i.v. Automation and IntelliFlowRx Pharmacy Workflow Manager products. The Baxa IntelliSource(TM) program offers health-system pharmacies access to the automation and software they need to ensure that each dose dispensed is safe and accurate - without making capital investments, paying one-time setup fees or signing capital leases.
The Medical Innovation Bill tabled by Lord Saatchi and currently making its way through the UK's House of Lords "strikes at the heart of evidence-based medicine" and risks "opening the door to the use of less proven, or unproven, approaches such as complementary or alternative medicine", according to a new Editorial published in The Lancet Oncology.
Around 20% of breast cancer patients do not complete prescribed endocrine therapy, researchers report at the ESMO Asia 2016 Congress in Singapore.1 The study in over 5,500 women found that younger patients and those who had taken hormone replacement therapy (HRT) were less likely to adhere to their medicine.
NextSource Biotechnology, LLC announced today that Gleostine (lomustine) 5 mg capsules has been approved by the U.S. Food and Drug Administration and is now commercially available in the United States.
› Verified 5 days ago
| Provider Name | Dominic John Roda |
|---|---|
| Provider Type | Practitioner - Podiatry |
| Provider Identifiers | NPI Number: 1407144264 PECOS PAC ID: 8426273491 Enrollment ID: I20140707001648 |
News Archive
Baxa Corporation announces the launch of a new program for sourcing its IntelliFill i.v. Automation and IntelliFlowRx Pharmacy Workflow Manager products. The Baxa IntelliSource(TM) program offers health-system pharmacies access to the automation and software they need to ensure that each dose dispensed is safe and accurate - without making capital investments, paying one-time setup fees or signing capital leases.
The Medical Innovation Bill tabled by Lord Saatchi and currently making its way through the UK's House of Lords "strikes at the heart of evidence-based medicine" and risks "opening the door to the use of less proven, or unproven, approaches such as complementary or alternative medicine", according to a new Editorial published in The Lancet Oncology.
Around 20% of breast cancer patients do not complete prescribed endocrine therapy, researchers report at the ESMO Asia 2016 Congress in Singapore.1 The study in over 5,500 women found that younger patients and those who had taken hormone replacement therapy (HRT) were less likely to adhere to their medicine.
NextSource Biotechnology, LLC announced today that Gleostine (lomustine) 5 mg capsules has been approved by the U.S. Food and Drug Administration and is now commercially available in the United States.
› Verified 5 days ago
| Provider Name | Teresa R Garris |
|---|---|
| Provider Type | Practitioner - Nurse Practitioner |
| Provider Identifiers | NPI Number: 1699194746 PECOS PAC ID: 5294952966 Enrollment ID: I20140805000446 |
News Archive
Baxa Corporation announces the launch of a new program for sourcing its IntelliFill i.v. Automation and IntelliFlowRx Pharmacy Workflow Manager products. The Baxa IntelliSource(TM) program offers health-system pharmacies access to the automation and software they need to ensure that each dose dispensed is safe and accurate - without making capital investments, paying one-time setup fees or signing capital leases.
The Medical Innovation Bill tabled by Lord Saatchi and currently making its way through the UK's House of Lords "strikes at the heart of evidence-based medicine" and risks "opening the door to the use of less proven, or unproven, approaches such as complementary or alternative medicine", according to a new Editorial published in The Lancet Oncology.
Around 20% of breast cancer patients do not complete prescribed endocrine therapy, researchers report at the ESMO Asia 2016 Congress in Singapore.1 The study in over 5,500 women found that younger patients and those who had taken hormone replacement therapy (HRT) were less likely to adhere to their medicine.
NextSource Biotechnology, LLC announced today that Gleostine (lomustine) 5 mg capsules has been approved by the U.S. Food and Drug Administration and is now commercially available in the United States.
› Verified 5 days ago
| Provider Name | Kristina H Lavoie |
|---|---|
| Provider Type | Practitioner - Clinical Social Worker |
| Provider Identifiers | NPI Number: 1487986881 PECOS PAC ID: 4789803636 Enrollment ID: I20140909000410 |
News Archive
Baxa Corporation announces the launch of a new program for sourcing its IntelliFill i.v. Automation and IntelliFlowRx Pharmacy Workflow Manager products. The Baxa IntelliSource(TM) program offers health-system pharmacies access to the automation and software they need to ensure that each dose dispensed is safe and accurate - without making capital investments, paying one-time setup fees or signing capital leases.
The Medical Innovation Bill tabled by Lord Saatchi and currently making its way through the UK's House of Lords "strikes at the heart of evidence-based medicine" and risks "opening the door to the use of less proven, or unproven, approaches such as complementary or alternative medicine", according to a new Editorial published in The Lancet Oncology.
Around 20% of breast cancer patients do not complete prescribed endocrine therapy, researchers report at the ESMO Asia 2016 Congress in Singapore.1 The study in over 5,500 women found that younger patients and those who had taken hormone replacement therapy (HRT) were less likely to adhere to their medicine.
NextSource Biotechnology, LLC announced today that Gleostine (lomustine) 5 mg capsules has been approved by the U.S. Food and Drug Administration and is now commercially available in the United States.
› Verified 5 days ago
| Provider Name | Cathy D Lindbeck |
|---|---|
| Provider Type | Practitioner - Certified Clinical Nurse Specialist (cns) |
| Provider Identifiers | NPI Number: 1831256221 PECOS PAC ID: 8123112158 Enrollment ID: I20150219002258 |
News Archive
Baxa Corporation announces the launch of a new program for sourcing its IntelliFill i.v. Automation and IntelliFlowRx Pharmacy Workflow Manager products. The Baxa IntelliSource(TM) program offers health-system pharmacies access to the automation and software they need to ensure that each dose dispensed is safe and accurate - without making capital investments, paying one-time setup fees or signing capital leases.
The Medical Innovation Bill tabled by Lord Saatchi and currently making its way through the UK's House of Lords "strikes at the heart of evidence-based medicine" and risks "opening the door to the use of less proven, or unproven, approaches such as complementary or alternative medicine", according to a new Editorial published in The Lancet Oncology.
Around 20% of breast cancer patients do not complete prescribed endocrine therapy, researchers report at the ESMO Asia 2016 Congress in Singapore.1 The study in over 5,500 women found that younger patients and those who had taken hormone replacement therapy (HRT) were less likely to adhere to their medicine.
NextSource Biotechnology, LLC announced today that Gleostine (lomustine) 5 mg capsules has been approved by the U.S. Food and Drug Administration and is now commercially available in the United States.
› Verified 5 days ago
| Provider Name | Mohamad Hamdi |
|---|---|
| Provider Type | Practitioner - Obstetrics/gynecology |
| Provider Identifiers | NPI Number: 1750570172 PECOS PAC ID: 7315125606 Enrollment ID: I20150811005250 |
News Archive
Baxa Corporation announces the launch of a new program for sourcing its IntelliFill i.v. Automation and IntelliFlowRx Pharmacy Workflow Manager products. The Baxa IntelliSource(TM) program offers health-system pharmacies access to the automation and software they need to ensure that each dose dispensed is safe and accurate - without making capital investments, paying one-time setup fees or signing capital leases.
The Medical Innovation Bill tabled by Lord Saatchi and currently making its way through the UK's House of Lords "strikes at the heart of evidence-based medicine" and risks "opening the door to the use of less proven, or unproven, approaches such as complementary or alternative medicine", according to a new Editorial published in The Lancet Oncology.
Around 20% of breast cancer patients do not complete prescribed endocrine therapy, researchers report at the ESMO Asia 2016 Congress in Singapore.1 The study in over 5,500 women found that younger patients and those who had taken hormone replacement therapy (HRT) were less likely to adhere to their medicine.
NextSource Biotechnology, LLC announced today that Gleostine (lomustine) 5 mg capsules has been approved by the U.S. Food and Drug Administration and is now commercially available in the United States.
› Verified 5 days ago
| Provider Name | Patrick Ofori-appiah |
|---|---|
| Provider Type | Practitioner - Clinical Social Worker |
| Provider Identifiers | NPI Number: 1508264920 PECOS PAC ID: 2567771710 Enrollment ID: I20151029000319 |
News Archive
Baxa Corporation announces the launch of a new program for sourcing its IntelliFill i.v. Automation and IntelliFlowRx Pharmacy Workflow Manager products. The Baxa IntelliSource(TM) program offers health-system pharmacies access to the automation and software they need to ensure that each dose dispensed is safe and accurate - without making capital investments, paying one-time setup fees or signing capital leases.
The Medical Innovation Bill tabled by Lord Saatchi and currently making its way through the UK's House of Lords "strikes at the heart of evidence-based medicine" and risks "opening the door to the use of less proven, or unproven, approaches such as complementary or alternative medicine", according to a new Editorial published in The Lancet Oncology.
Around 20% of breast cancer patients do not complete prescribed endocrine therapy, researchers report at the ESMO Asia 2016 Congress in Singapore.1 The study in over 5,500 women found that younger patients and those who had taken hormone replacement therapy (HRT) were less likely to adhere to their medicine.
NextSource Biotechnology, LLC announced today that Gleostine (lomustine) 5 mg capsules has been approved by the U.S. Food and Drug Administration and is now commercially available in the United States.
› Verified 5 days ago
| Provider Name | Thomas Owen Genese |
|---|---|
| Provider Type | Practitioner - Internal Medicine |
| Provider Identifiers | NPI Number: 1922111632 PECOS PAC ID: 7012070360 Enrollment ID: I20151203002157 |
News Archive
Baxa Corporation announces the launch of a new program for sourcing its IntelliFill i.v. Automation and IntelliFlowRx Pharmacy Workflow Manager products. The Baxa IntelliSource(TM) program offers health-system pharmacies access to the automation and software they need to ensure that each dose dispensed is safe and accurate - without making capital investments, paying one-time setup fees or signing capital leases.
The Medical Innovation Bill tabled by Lord Saatchi and currently making its way through the UK's House of Lords "strikes at the heart of evidence-based medicine" and risks "opening the door to the use of less proven, or unproven, approaches such as complementary or alternative medicine", according to a new Editorial published in The Lancet Oncology.
Around 20% of breast cancer patients do not complete prescribed endocrine therapy, researchers report at the ESMO Asia 2016 Congress in Singapore.1 The study in over 5,500 women found that younger patients and those who had taken hormone replacement therapy (HRT) were less likely to adhere to their medicine.
NextSource Biotechnology, LLC announced today that Gleostine (lomustine) 5 mg capsules has been approved by the U.S. Food and Drug Administration and is now commercially available in the United States.
› Verified 5 days ago
| Provider Name | Shera Baker |
|---|---|
| Provider Type | Practitioner - Clinical Social Worker |
| Provider Identifiers | NPI Number: 1356786826 PECOS PAC ID: 9931403482 Enrollment ID: I20160204000165 |
News Archive
Baxa Corporation announces the launch of a new program for sourcing its IntelliFill i.v. Automation and IntelliFlowRx Pharmacy Workflow Manager products. The Baxa IntelliSource(TM) program offers health-system pharmacies access to the automation and software they need to ensure that each dose dispensed is safe and accurate - without making capital investments, paying one-time setup fees or signing capital leases.
The Medical Innovation Bill tabled by Lord Saatchi and currently making its way through the UK's House of Lords "strikes at the heart of evidence-based medicine" and risks "opening the door to the use of less proven, or unproven, approaches such as complementary or alternative medicine", according to a new Editorial published in The Lancet Oncology.
Around 20% of breast cancer patients do not complete prescribed endocrine therapy, researchers report at the ESMO Asia 2016 Congress in Singapore.1 The study in over 5,500 women found that younger patients and those who had taken hormone replacement therapy (HRT) were less likely to adhere to their medicine.
NextSource Biotechnology, LLC announced today that Gleostine (lomustine) 5 mg capsules has been approved by the U.S. Food and Drug Administration and is now commercially available in the United States.
› Verified 5 days ago
| Provider Name | Crystal Souza |
|---|---|
| Provider Type | Practitioner - Nurse Practitioner |
| Provider Identifiers | NPI Number: 1467826693 PECOS PAC ID: 2668776766 Enrollment ID: I20160210001953 |
News Archive
Baxa Corporation announces the launch of a new program for sourcing its IntelliFill i.v. Automation and IntelliFlowRx Pharmacy Workflow Manager products. The Baxa IntelliSource(TM) program offers health-system pharmacies access to the automation and software they need to ensure that each dose dispensed is safe and accurate - without making capital investments, paying one-time setup fees or signing capital leases.
The Medical Innovation Bill tabled by Lord Saatchi and currently making its way through the UK's House of Lords "strikes at the heart of evidence-based medicine" and risks "opening the door to the use of less proven, or unproven, approaches such as complementary or alternative medicine", according to a new Editorial published in The Lancet Oncology.
Around 20% of breast cancer patients do not complete prescribed endocrine therapy, researchers report at the ESMO Asia 2016 Congress in Singapore.1 The study in over 5,500 women found that younger patients and those who had taken hormone replacement therapy (HRT) were less likely to adhere to their medicine.
NextSource Biotechnology, LLC announced today that Gleostine (lomustine) 5 mg capsules has been approved by the U.S. Food and Drug Administration and is now commercially available in the United States.
› Verified 5 days ago
| Provider Name | Eunice H Wharton |
|---|---|
| Provider Type | Practitioner - Clinical Social Worker |
| Provider Identifiers | NPI Number: 1629214929 PECOS PAC ID: 9638474133 Enrollment ID: I20160222000969 |
News Archive
Baxa Corporation announces the launch of a new program for sourcing its IntelliFill i.v. Automation and IntelliFlowRx Pharmacy Workflow Manager products. The Baxa IntelliSource(TM) program offers health-system pharmacies access to the automation and software they need to ensure that each dose dispensed is safe and accurate - without making capital investments, paying one-time setup fees or signing capital leases.
The Medical Innovation Bill tabled by Lord Saatchi and currently making its way through the UK's House of Lords "strikes at the heart of evidence-based medicine" and risks "opening the door to the use of less proven, or unproven, approaches such as complementary or alternative medicine", according to a new Editorial published in The Lancet Oncology.
Around 20% of breast cancer patients do not complete prescribed endocrine therapy, researchers report at the ESMO Asia 2016 Congress in Singapore.1 The study in over 5,500 women found that younger patients and those who had taken hormone replacement therapy (HRT) were less likely to adhere to their medicine.
NextSource Biotechnology, LLC announced today that Gleostine (lomustine) 5 mg capsules has been approved by the U.S. Food and Drug Administration and is now commercially available in the United States.
› Verified 5 days ago
| Provider Name | Quinn Flatley |
|---|---|
| Provider Type | Practitioner - Clinical Social Worker |
| Provider Identifiers | NPI Number: 1689966764 PECOS PAC ID: 0547566432 Enrollment ID: I20160302001139 |
News Archive
Baxa Corporation announces the launch of a new program for sourcing its IntelliFill i.v. Automation and IntelliFlowRx Pharmacy Workflow Manager products. The Baxa IntelliSource(TM) program offers health-system pharmacies access to the automation and software they need to ensure that each dose dispensed is safe and accurate - without making capital investments, paying one-time setup fees or signing capital leases.
The Medical Innovation Bill tabled by Lord Saatchi and currently making its way through the UK's House of Lords "strikes at the heart of evidence-based medicine" and risks "opening the door to the use of less proven, or unproven, approaches such as complementary or alternative medicine", according to a new Editorial published in The Lancet Oncology.
Around 20% of breast cancer patients do not complete prescribed endocrine therapy, researchers report at the ESMO Asia 2016 Congress in Singapore.1 The study in over 5,500 women found that younger patients and those who had taken hormone replacement therapy (HRT) were less likely to adhere to their medicine.
NextSource Biotechnology, LLC announced today that Gleostine (lomustine) 5 mg capsules has been approved by the U.S. Food and Drug Administration and is now commercially available in the United States.
› Verified 5 days ago
| Provider Name | Bridget Kelly |
|---|---|
| Provider Type | Practitioner - Obstetrics/gynecology |
| Provider Identifiers | NPI Number: 1851636369 PECOS PAC ID: 9537451810 Enrollment ID: I20160706002109 |
News Archive
Baxa Corporation announces the launch of a new program for sourcing its IntelliFill i.v. Automation and IntelliFlowRx Pharmacy Workflow Manager products. The Baxa IntelliSource(TM) program offers health-system pharmacies access to the automation and software they need to ensure that each dose dispensed is safe and accurate - without making capital investments, paying one-time setup fees or signing capital leases.
The Medical Innovation Bill tabled by Lord Saatchi and currently making its way through the UK's House of Lords "strikes at the heart of evidence-based medicine" and risks "opening the door to the use of less proven, or unproven, approaches such as complementary or alternative medicine", according to a new Editorial published in The Lancet Oncology.
Around 20% of breast cancer patients do not complete prescribed endocrine therapy, researchers report at the ESMO Asia 2016 Congress in Singapore.1 The study in over 5,500 women found that younger patients and those who had taken hormone replacement therapy (HRT) were less likely to adhere to their medicine.
NextSource Biotechnology, LLC announced today that Gleostine (lomustine) 5 mg capsules has been approved by the U.S. Food and Drug Administration and is now commercially available in the United States.
› Verified 5 days ago
| Provider Name | Rodrigo Nardi |
|---|---|
| Provider Type | Practitioner - Psychiatry |
| Provider Identifiers | NPI Number: 1679837876 PECOS PAC ID: 4284875717 Enrollment ID: I20160826001981 |
News Archive
Baxa Corporation announces the launch of a new program for sourcing its IntelliFill i.v. Automation and IntelliFlowRx Pharmacy Workflow Manager products. The Baxa IntelliSource(TM) program offers health-system pharmacies access to the automation and software they need to ensure that each dose dispensed is safe and accurate - without making capital investments, paying one-time setup fees or signing capital leases.
The Medical Innovation Bill tabled by Lord Saatchi and currently making its way through the UK's House of Lords "strikes at the heart of evidence-based medicine" and risks "opening the door to the use of less proven, or unproven, approaches such as complementary or alternative medicine", according to a new Editorial published in The Lancet Oncology.
Around 20% of breast cancer patients do not complete prescribed endocrine therapy, researchers report at the ESMO Asia 2016 Congress in Singapore.1 The study in over 5,500 women found that younger patients and those who had taken hormone replacement therapy (HRT) were less likely to adhere to their medicine.
NextSource Biotechnology, LLC announced today that Gleostine (lomustine) 5 mg capsules has been approved by the U.S. Food and Drug Administration and is now commercially available in the United States.
› Verified 5 days ago
| Provider Name | Kate B Noveau |
|---|---|
| Provider Type | Practitioner - Clinical Social Worker |
| Provider Identifiers | NPI Number: 1255423430 PECOS PAC ID: 7810278421 Enrollment ID: I20161219002013 |
News Archive
Baxa Corporation announces the launch of a new program for sourcing its IntelliFill i.v. Automation and IntelliFlowRx Pharmacy Workflow Manager products. The Baxa IntelliSource(TM) program offers health-system pharmacies access to the automation and software they need to ensure that each dose dispensed is safe and accurate - without making capital investments, paying one-time setup fees or signing capital leases.
The Medical Innovation Bill tabled by Lord Saatchi and currently making its way through the UK's House of Lords "strikes at the heart of evidence-based medicine" and risks "opening the door to the use of less proven, or unproven, approaches such as complementary or alternative medicine", according to a new Editorial published in The Lancet Oncology.
Around 20% of breast cancer patients do not complete prescribed endocrine therapy, researchers report at the ESMO Asia 2016 Congress in Singapore.1 The study in over 5,500 women found that younger patients and those who had taken hormone replacement therapy (HRT) were less likely to adhere to their medicine.
NextSource Biotechnology, LLC announced today that Gleostine (lomustine) 5 mg capsules has been approved by the U.S. Food and Drug Administration and is now commercially available in the United States.
› Verified 5 days ago
| Provider Name | Margaret Frempong |
|---|---|
| Provider Type | Practitioner - Clinical Social Worker |
| Provider Identifiers | NPI Number: 1508176090 PECOS PAC ID: 8820371107 Enrollment ID: I20170210001881 |
News Archive
Baxa Corporation announces the launch of a new program for sourcing its IntelliFill i.v. Automation and IntelliFlowRx Pharmacy Workflow Manager products. The Baxa IntelliSource(TM) program offers health-system pharmacies access to the automation and software they need to ensure that each dose dispensed is safe and accurate - without making capital investments, paying one-time setup fees or signing capital leases.
The Medical Innovation Bill tabled by Lord Saatchi and currently making its way through the UK's House of Lords "strikes at the heart of evidence-based medicine" and risks "opening the door to the use of less proven, or unproven, approaches such as complementary or alternative medicine", according to a new Editorial published in The Lancet Oncology.
Around 20% of breast cancer patients do not complete prescribed endocrine therapy, researchers report at the ESMO Asia 2016 Congress in Singapore.1 The study in over 5,500 women found that younger patients and those who had taken hormone replacement therapy (HRT) were less likely to adhere to their medicine.
NextSource Biotechnology, LLC announced today that Gleostine (lomustine) 5 mg capsules has been approved by the U.S. Food and Drug Administration and is now commercially available in the United States.
› Verified 5 days ago
| Provider Name | Kathryn E Mccullough |
|---|---|
| Provider Type | Practitioner - Clinical Social Worker |
| Provider Identifiers | NPI Number: 1578014098 PECOS PAC ID: 9739308388 Enrollment ID: I20170223000152 |
News Archive
Baxa Corporation announces the launch of a new program for sourcing its IntelliFill i.v. Automation and IntelliFlowRx Pharmacy Workflow Manager products. The Baxa IntelliSource(TM) program offers health-system pharmacies access to the automation and software they need to ensure that each dose dispensed is safe and accurate - without making capital investments, paying one-time setup fees or signing capital leases.
The Medical Innovation Bill tabled by Lord Saatchi and currently making its way through the UK's House of Lords "strikes at the heart of evidence-based medicine" and risks "opening the door to the use of less proven, or unproven, approaches such as complementary or alternative medicine", according to a new Editorial published in The Lancet Oncology.
Around 20% of breast cancer patients do not complete prescribed endocrine therapy, researchers report at the ESMO Asia 2016 Congress in Singapore.1 The study in over 5,500 women found that younger patients and those who had taken hormone replacement therapy (HRT) were less likely to adhere to their medicine.
NextSource Biotechnology, LLC announced today that Gleostine (lomustine) 5 mg capsules has been approved by the U.S. Food and Drug Administration and is now commercially available in the United States.
› Verified 5 days ago
| Provider Name | Dennis Goulet |
|---|---|
| Provider Type | Practitioner - Obstetrics/gynecology |
| Provider Identifiers | NPI Number: 1326488925 PECOS PAC ID: 2163728619 Enrollment ID: I20170627001880 |
News Archive
Baxa Corporation announces the launch of a new program for sourcing its IntelliFill i.v. Automation and IntelliFlowRx Pharmacy Workflow Manager products. The Baxa IntelliSource(TM) program offers health-system pharmacies access to the automation and software they need to ensure that each dose dispensed is safe and accurate - without making capital investments, paying one-time setup fees or signing capital leases.
The Medical Innovation Bill tabled by Lord Saatchi and currently making its way through the UK's House of Lords "strikes at the heart of evidence-based medicine" and risks "opening the door to the use of less proven, or unproven, approaches such as complementary or alternative medicine", according to a new Editorial published in The Lancet Oncology.
Around 20% of breast cancer patients do not complete prescribed endocrine therapy, researchers report at the ESMO Asia 2016 Congress in Singapore.1 The study in over 5,500 women found that younger patients and those who had taken hormone replacement therapy (HRT) were less likely to adhere to their medicine.
NextSource Biotechnology, LLC announced today that Gleostine (lomustine) 5 mg capsules has been approved by the U.S. Food and Drug Administration and is now commercially available in the United States.
› Verified 5 days ago
| Provider Name | Rosalie Ann Camacho |
|---|---|
| Provider Type | Practitioner - Clinical Social Worker |
| Provider Identifiers | NPI Number: 1508385568 PECOS PAC ID: 6608141015 Enrollment ID: I20171011002661 |
News Archive
Baxa Corporation announces the launch of a new program for sourcing its IntelliFill i.v. Automation and IntelliFlowRx Pharmacy Workflow Manager products. The Baxa IntelliSource(TM) program offers health-system pharmacies access to the automation and software they need to ensure that each dose dispensed is safe and accurate - without making capital investments, paying one-time setup fees or signing capital leases.
The Medical Innovation Bill tabled by Lord Saatchi and currently making its way through the UK's House of Lords "strikes at the heart of evidence-based medicine" and risks "opening the door to the use of less proven, or unproven, approaches such as complementary or alternative medicine", according to a new Editorial published in The Lancet Oncology.
Around 20% of breast cancer patients do not complete prescribed endocrine therapy, researchers report at the ESMO Asia 2016 Congress in Singapore.1 The study in over 5,500 women found that younger patients and those who had taken hormone replacement therapy (HRT) were less likely to adhere to their medicine.
NextSource Biotechnology, LLC announced today that Gleostine (lomustine) 5 mg capsules has been approved by the U.S. Food and Drug Administration and is now commercially available in the United States.
› Verified 5 days ago
| Provider Name | Olga L Morrone |
|---|---|
| Provider Type | Practitioner - Nurse Practitioner |
| Provider Identifiers | NPI Number: 1801315098 PECOS PAC ID: 4880952688 Enrollment ID: I20171228001083 |
News Archive
Baxa Corporation announces the launch of a new program for sourcing its IntelliFill i.v. Automation and IntelliFlowRx Pharmacy Workflow Manager products. The Baxa IntelliSource(TM) program offers health-system pharmacies access to the automation and software they need to ensure that each dose dispensed is safe and accurate - without making capital investments, paying one-time setup fees or signing capital leases.
The Medical Innovation Bill tabled by Lord Saatchi and currently making its way through the UK's House of Lords "strikes at the heart of evidence-based medicine" and risks "opening the door to the use of less proven, or unproven, approaches such as complementary or alternative medicine", according to a new Editorial published in The Lancet Oncology.
Around 20% of breast cancer patients do not complete prescribed endocrine therapy, researchers report at the ESMO Asia 2016 Congress in Singapore.1 The study in over 5,500 women found that younger patients and those who had taken hormone replacement therapy (HRT) were less likely to adhere to their medicine.
NextSource Biotechnology, LLC announced today that Gleostine (lomustine) 5 mg capsules has been approved by the U.S. Food and Drug Administration and is now commercially available in the United States.
› Verified 5 days ago
| Provider Name | Meredith E Sinel |
|---|---|
| Provider Type | Practitioner - Clinical Social Worker |
| Provider Identifiers | NPI Number: 1487059895 PECOS PAC ID: 3072874817 Enrollment ID: I20180219002016 |
News Archive
Baxa Corporation announces the launch of a new program for sourcing its IntelliFill i.v. Automation and IntelliFlowRx Pharmacy Workflow Manager products. The Baxa IntelliSource(TM) program offers health-system pharmacies access to the automation and software they need to ensure that each dose dispensed is safe and accurate - without making capital investments, paying one-time setup fees or signing capital leases.
The Medical Innovation Bill tabled by Lord Saatchi and currently making its way through the UK's House of Lords "strikes at the heart of evidence-based medicine" and risks "opening the door to the use of less proven, or unproven, approaches such as complementary or alternative medicine", according to a new Editorial published in The Lancet Oncology.
Around 20% of breast cancer patients do not complete prescribed endocrine therapy, researchers report at the ESMO Asia 2016 Congress in Singapore.1 The study in over 5,500 women found that younger patients and those who had taken hormone replacement therapy (HRT) were less likely to adhere to their medicine.
NextSource Biotechnology, LLC announced today that Gleostine (lomustine) 5 mg capsules has been approved by the U.S. Food and Drug Administration and is now commercially available in the United States.
› Verified 5 days ago
| Provider Name | Caitlin S Mcardle |
|---|---|
| Provider Type | Practitioner - Clinical Social Worker |
| Provider Identifiers | NPI Number: 1508307240 PECOS PAC ID: 5092076794 Enrollment ID: I20180220002164 |
News Archive
Baxa Corporation announces the launch of a new program for sourcing its IntelliFill i.v. Automation and IntelliFlowRx Pharmacy Workflow Manager products. The Baxa IntelliSource(TM) program offers health-system pharmacies access to the automation and software they need to ensure that each dose dispensed is safe and accurate - without making capital investments, paying one-time setup fees or signing capital leases.
The Medical Innovation Bill tabled by Lord Saatchi and currently making its way through the UK's House of Lords "strikes at the heart of evidence-based medicine" and risks "opening the door to the use of less proven, or unproven, approaches such as complementary or alternative medicine", according to a new Editorial published in The Lancet Oncology.
Around 20% of breast cancer patients do not complete prescribed endocrine therapy, researchers report at the ESMO Asia 2016 Congress in Singapore.1 The study in over 5,500 women found that younger patients and those who had taken hormone replacement therapy (HRT) were less likely to adhere to their medicine.
NextSource Biotechnology, LLC announced today that Gleostine (lomustine) 5 mg capsules has been approved by the U.S. Food and Drug Administration and is now commercially available in the United States.
› Verified 5 days ago
| Provider Name | Yuli Y Paula |
|---|---|
| Provider Type | Practitioner - Clinical Social Worker |
| Provider Identifiers | NPI Number: 1487038584 PECOS PAC ID: 2769743418 Enrollment ID: I20180221001192 |
News Archive
Baxa Corporation announces the launch of a new program for sourcing its IntelliFill i.v. Automation and IntelliFlowRx Pharmacy Workflow Manager products. The Baxa IntelliSource(TM) program offers health-system pharmacies access to the automation and software they need to ensure that each dose dispensed is safe and accurate - without making capital investments, paying one-time setup fees or signing capital leases.
The Medical Innovation Bill tabled by Lord Saatchi and currently making its way through the UK's House of Lords "strikes at the heart of evidence-based medicine" and risks "opening the door to the use of less proven, or unproven, approaches such as complementary or alternative medicine", according to a new Editorial published in The Lancet Oncology.
Around 20% of breast cancer patients do not complete prescribed endocrine therapy, researchers report at the ESMO Asia 2016 Congress in Singapore.1 The study in over 5,500 women found that younger patients and those who had taken hormone replacement therapy (HRT) were less likely to adhere to their medicine.
NextSource Biotechnology, LLC announced today that Gleostine (lomustine) 5 mg capsules has been approved by the U.S. Food and Drug Administration and is now commercially available in the United States.
› Verified 5 days ago
| Provider Name | Emily J Dimon |
|---|---|
| Provider Type | Practitioner - Clinical Social Worker |
| Provider Identifiers | NPI Number: 1326560004 PECOS PAC ID: 9830450337 Enrollment ID: I20180226000484 |
News Archive
Baxa Corporation announces the launch of a new program for sourcing its IntelliFill i.v. Automation and IntelliFlowRx Pharmacy Workflow Manager products. The Baxa IntelliSource(TM) program offers health-system pharmacies access to the automation and software they need to ensure that each dose dispensed is safe and accurate - without making capital investments, paying one-time setup fees or signing capital leases.
The Medical Innovation Bill tabled by Lord Saatchi and currently making its way through the UK's House of Lords "strikes at the heart of evidence-based medicine" and risks "opening the door to the use of less proven, or unproven, approaches such as complementary or alternative medicine", according to a new Editorial published in The Lancet Oncology.
Around 20% of breast cancer patients do not complete prescribed endocrine therapy, researchers report at the ESMO Asia 2016 Congress in Singapore.1 The study in over 5,500 women found that younger patients and those who had taken hormone replacement therapy (HRT) were less likely to adhere to their medicine.
NextSource Biotechnology, LLC announced today that Gleostine (lomustine) 5 mg capsules has been approved by the U.S. Food and Drug Administration and is now commercially available in the United States.
› Verified 5 days ago
| Provider Name | Kalpana R Polu |
|---|---|
| Provider Type | Practitioner - Psychiatry |
| Provider Identifiers | NPI Number: 1740219534 PECOS PAC ID: 9739172875 Enrollment ID: I20180301000455 |
News Archive
Baxa Corporation announces the launch of a new program for sourcing its IntelliFill i.v. Automation and IntelliFlowRx Pharmacy Workflow Manager products. The Baxa IntelliSource(TM) program offers health-system pharmacies access to the automation and software they need to ensure that each dose dispensed is safe and accurate - without making capital investments, paying one-time setup fees or signing capital leases.
The Medical Innovation Bill tabled by Lord Saatchi and currently making its way through the UK's House of Lords "strikes at the heart of evidence-based medicine" and risks "opening the door to the use of less proven, or unproven, approaches such as complementary or alternative medicine", according to a new Editorial published in The Lancet Oncology.
Around 20% of breast cancer patients do not complete prescribed endocrine therapy, researchers report at the ESMO Asia 2016 Congress in Singapore.1 The study in over 5,500 women found that younger patients and those who had taken hormone replacement therapy (HRT) were less likely to adhere to their medicine.
NextSource Biotechnology, LLC announced today that Gleostine (lomustine) 5 mg capsules has been approved by the U.S. Food and Drug Administration and is now commercially available in the United States.
› Verified 5 days ago
| Provider Name | Heather Seger |
|---|---|
| Provider Type | Practitioner - Clinical Social Worker |
| Provider Identifiers | NPI Number: 1427595602 PECOS PAC ID: 5294097416 Enrollment ID: I20180327002101 |
News Archive
Baxa Corporation announces the launch of a new program for sourcing its IntelliFill i.v. Automation and IntelliFlowRx Pharmacy Workflow Manager products. The Baxa IntelliSource(TM) program offers health-system pharmacies access to the automation and software they need to ensure that each dose dispensed is safe and accurate - without making capital investments, paying one-time setup fees or signing capital leases.
The Medical Innovation Bill tabled by Lord Saatchi and currently making its way through the UK's House of Lords "strikes at the heart of evidence-based medicine" and risks "opening the door to the use of less proven, or unproven, approaches such as complementary or alternative medicine", according to a new Editorial published in The Lancet Oncology.
Around 20% of breast cancer patients do not complete prescribed endocrine therapy, researchers report at the ESMO Asia 2016 Congress in Singapore.1 The study in over 5,500 women found that younger patients and those who had taken hormone replacement therapy (HRT) were less likely to adhere to their medicine.
NextSource Biotechnology, LLC announced today that Gleostine (lomustine) 5 mg capsules has been approved by the U.S. Food and Drug Administration and is now commercially available in the United States.
› Verified 5 days ago
| Provider Name | R Bhawani Prasad |
|---|---|
| Provider Type | Practitioner - Psychiatry |
| Provider Identifiers | NPI Number: 1679534994 PECOS PAC ID: 2668510306 Enrollment ID: I20180406000713 |
News Archive
Baxa Corporation announces the launch of a new program for sourcing its IntelliFill i.v. Automation and IntelliFlowRx Pharmacy Workflow Manager products. The Baxa IntelliSource(TM) program offers health-system pharmacies access to the automation and software they need to ensure that each dose dispensed is safe and accurate - without making capital investments, paying one-time setup fees or signing capital leases.
The Medical Innovation Bill tabled by Lord Saatchi and currently making its way through the UK's House of Lords "strikes at the heart of evidence-based medicine" and risks "opening the door to the use of less proven, or unproven, approaches such as complementary or alternative medicine", according to a new Editorial published in The Lancet Oncology.
Around 20% of breast cancer patients do not complete prescribed endocrine therapy, researchers report at the ESMO Asia 2016 Congress in Singapore.1 The study in over 5,500 women found that younger patients and those who had taken hormone replacement therapy (HRT) were less likely to adhere to their medicine.
NextSource Biotechnology, LLC announced today that Gleostine (lomustine) 5 mg capsules has been approved by the U.S. Food and Drug Administration and is now commercially available in the United States.
› Verified 5 days ago
| Provider Name | Kendra Apici |
|---|---|
| Provider Type | Practitioner - Clinical Social Worker |
| Provider Identifiers | NPI Number: 1306368881 PECOS PAC ID: 7911252044 Enrollment ID: I20180613003070 |
News Archive
Baxa Corporation announces the launch of a new program for sourcing its IntelliFill i.v. Automation and IntelliFlowRx Pharmacy Workflow Manager products. The Baxa IntelliSource(TM) program offers health-system pharmacies access to the automation and software they need to ensure that each dose dispensed is safe and accurate - without making capital investments, paying one-time setup fees or signing capital leases.
The Medical Innovation Bill tabled by Lord Saatchi and currently making its way through the UK's House of Lords "strikes at the heart of evidence-based medicine" and risks "opening the door to the use of less proven, or unproven, approaches such as complementary or alternative medicine", according to a new Editorial published in The Lancet Oncology.
Around 20% of breast cancer patients do not complete prescribed endocrine therapy, researchers report at the ESMO Asia 2016 Congress in Singapore.1 The study in over 5,500 women found that younger patients and those who had taken hormone replacement therapy (HRT) were less likely to adhere to their medicine.
NextSource Biotechnology, LLC announced today that Gleostine (lomustine) 5 mg capsules has been approved by the U.S. Food and Drug Administration and is now commercially available in the United States.
› Verified 5 days ago
| Provider Name | Simon F Desjardins |
|---|---|
| Provider Type | Practitioner - Psychiatry |
| Provider Identifiers | NPI Number: 1821387580 PECOS PAC ID: 5294035101 Enrollment ID: I20180614000162 |
News Archive
Baxa Corporation announces the launch of a new program for sourcing its IntelliFill i.v. Automation and IntelliFlowRx Pharmacy Workflow Manager products. The Baxa IntelliSource(TM) program offers health-system pharmacies access to the automation and software they need to ensure that each dose dispensed is safe and accurate - without making capital investments, paying one-time setup fees or signing capital leases.
The Medical Innovation Bill tabled by Lord Saatchi and currently making its way through the UK's House of Lords "strikes at the heart of evidence-based medicine" and risks "opening the door to the use of less proven, or unproven, approaches such as complementary or alternative medicine", according to a new Editorial published in The Lancet Oncology.
Around 20% of breast cancer patients do not complete prescribed endocrine therapy, researchers report at the ESMO Asia 2016 Congress in Singapore.1 The study in over 5,500 women found that younger patients and those who had taken hormone replacement therapy (HRT) were less likely to adhere to their medicine.
NextSource Biotechnology, LLC announced today that Gleostine (lomustine) 5 mg capsules has been approved by the U.S. Food and Drug Administration and is now commercially available in the United States.
› Verified 5 days ago
| Provider Name | Rachel J Armada |
|---|---|
| Provider Type | Practitioner - Clinical Social Worker |
| Provider Identifiers | NPI Number: 1548754484 PECOS PAC ID: 4880938877 Enrollment ID: I20181203000330 |
News Archive
Baxa Corporation announces the launch of a new program for sourcing its IntelliFill i.v. Automation and IntelliFlowRx Pharmacy Workflow Manager products. The Baxa IntelliSource(TM) program offers health-system pharmacies access to the automation and software they need to ensure that each dose dispensed is safe and accurate - without making capital investments, paying one-time setup fees or signing capital leases.
The Medical Innovation Bill tabled by Lord Saatchi and currently making its way through the UK's House of Lords "strikes at the heart of evidence-based medicine" and risks "opening the door to the use of less proven, or unproven, approaches such as complementary or alternative medicine", according to a new Editorial published in The Lancet Oncology.
Around 20% of breast cancer patients do not complete prescribed endocrine therapy, researchers report at the ESMO Asia 2016 Congress in Singapore.1 The study in over 5,500 women found that younger patients and those who had taken hormone replacement therapy (HRT) were less likely to adhere to their medicine.
NextSource Biotechnology, LLC announced today that Gleostine (lomustine) 5 mg capsules has been approved by the U.S. Food and Drug Administration and is now commercially available in the United States.
› Verified 5 days ago
| Provider Name | Yun Li |
|---|---|
| Provider Type | Practitioner - Clinical Social Worker |
| Provider Identifiers | NPI Number: 1376868737 PECOS PAC ID: 9032456801 Enrollment ID: I20190201000315 |
News Archive
Baxa Corporation announces the launch of a new program for sourcing its IntelliFill i.v. Automation and IntelliFlowRx Pharmacy Workflow Manager products. The Baxa IntelliSource(TM) program offers health-system pharmacies access to the automation and software they need to ensure that each dose dispensed is safe and accurate - without making capital investments, paying one-time setup fees or signing capital leases.
The Medical Innovation Bill tabled by Lord Saatchi and currently making its way through the UK's House of Lords "strikes at the heart of evidence-based medicine" and risks "opening the door to the use of less proven, or unproven, approaches such as complementary or alternative medicine", according to a new Editorial published in The Lancet Oncology.
Around 20% of breast cancer patients do not complete prescribed endocrine therapy, researchers report at the ESMO Asia 2016 Congress in Singapore.1 The study in over 5,500 women found that younger patients and those who had taken hormone replacement therapy (HRT) were less likely to adhere to their medicine.
NextSource Biotechnology, LLC announced today that Gleostine (lomustine) 5 mg capsules has been approved by the U.S. Food and Drug Administration and is now commercially available in the United States.
› Verified 5 days ago
| Provider Name | Patricia J Grendell |
|---|---|
| Provider Type | Practitioner - Nurse Practitioner |
| Provider Identifiers | NPI Number: 1609006949 PECOS PAC ID: 2567709280 Enrollment ID: I20190202000180 |
News Archive
Baxa Corporation announces the launch of a new program for sourcing its IntelliFill i.v. Automation and IntelliFlowRx Pharmacy Workflow Manager products. The Baxa IntelliSource(TM) program offers health-system pharmacies access to the automation and software they need to ensure that each dose dispensed is safe and accurate - without making capital investments, paying one-time setup fees or signing capital leases.
The Medical Innovation Bill tabled by Lord Saatchi and currently making its way through the UK's House of Lords "strikes at the heart of evidence-based medicine" and risks "opening the door to the use of less proven, or unproven, approaches such as complementary or alternative medicine", according to a new Editorial published in The Lancet Oncology.
Around 20% of breast cancer patients do not complete prescribed endocrine therapy, researchers report at the ESMO Asia 2016 Congress in Singapore.1 The study in over 5,500 women found that younger patients and those who had taken hormone replacement therapy (HRT) were less likely to adhere to their medicine.
NextSource Biotechnology, LLC announced today that Gleostine (lomustine) 5 mg capsules has been approved by the U.S. Food and Drug Administration and is now commercially available in the United States.
› Verified 5 days ago
| Provider Name | Ainsley K Parker |
|---|---|
| Provider Type | Practitioner - Clinical Social Worker |
| Provider Identifiers | NPI Number: 1366913873 PECOS PAC ID: 5496093684 Enrollment ID: I20190213002394 |
News Archive
Baxa Corporation announces the launch of a new program for sourcing its IntelliFill i.v. Automation and IntelliFlowRx Pharmacy Workflow Manager products. The Baxa IntelliSource(TM) program offers health-system pharmacies access to the automation and software they need to ensure that each dose dispensed is safe and accurate - without making capital investments, paying one-time setup fees or signing capital leases.
The Medical Innovation Bill tabled by Lord Saatchi and currently making its way through the UK's House of Lords "strikes at the heart of evidence-based medicine" and risks "opening the door to the use of less proven, or unproven, approaches such as complementary or alternative medicine", according to a new Editorial published in The Lancet Oncology.
Around 20% of breast cancer patients do not complete prescribed endocrine therapy, researchers report at the ESMO Asia 2016 Congress in Singapore.1 The study in over 5,500 women found that younger patients and those who had taken hormone replacement therapy (HRT) were less likely to adhere to their medicine.
NextSource Biotechnology, LLC announced today that Gleostine (lomustine) 5 mg capsules has been approved by the U.S. Food and Drug Administration and is now commercially available in the United States.
› Verified 5 days ago
| Provider Name | Asra Jawed |
|---|---|
| Provider Type | Practitioner - Obstetrics/gynecology |
| Provider Identifiers | NPI Number: 1235535386 PECOS PAC ID: 2466746664 Enrollment ID: I20190220002984 |
News Archive
Baxa Corporation announces the launch of a new program for sourcing its IntelliFill i.v. Automation and IntelliFlowRx Pharmacy Workflow Manager products. The Baxa IntelliSource(TM) program offers health-system pharmacies access to the automation and software they need to ensure that each dose dispensed is safe and accurate - without making capital investments, paying one-time setup fees or signing capital leases.
The Medical Innovation Bill tabled by Lord Saatchi and currently making its way through the UK's House of Lords "strikes at the heart of evidence-based medicine" and risks "opening the door to the use of less proven, or unproven, approaches such as complementary or alternative medicine", according to a new Editorial published in The Lancet Oncology.
Around 20% of breast cancer patients do not complete prescribed endocrine therapy, researchers report at the ESMO Asia 2016 Congress in Singapore.1 The study in over 5,500 women found that younger patients and those who had taken hormone replacement therapy (HRT) were less likely to adhere to their medicine.
NextSource Biotechnology, LLC announced today that Gleostine (lomustine) 5 mg capsules has been approved by the U.S. Food and Drug Administration and is now commercially available in the United States.
› Verified 5 days ago
| Provider Name | Kim P Raposo Busa |
|---|---|
| Provider Type | Practitioner - Nurse Practitioner |
| Provider Identifiers | NPI Number: 1457583247 PECOS PAC ID: 3577690197 Enrollment ID: I20190430002238 |
News Archive
Baxa Corporation announces the launch of a new program for sourcing its IntelliFill i.v. Automation and IntelliFlowRx Pharmacy Workflow Manager products. The Baxa IntelliSource(TM) program offers health-system pharmacies access to the automation and software they need to ensure that each dose dispensed is safe and accurate - without making capital investments, paying one-time setup fees or signing capital leases.
The Medical Innovation Bill tabled by Lord Saatchi and currently making its way through the UK's House of Lords "strikes at the heart of evidence-based medicine" and risks "opening the door to the use of less proven, or unproven, approaches such as complementary or alternative medicine", according to a new Editorial published in The Lancet Oncology.
Around 20% of breast cancer patients do not complete prescribed endocrine therapy, researchers report at the ESMO Asia 2016 Congress in Singapore.1 The study in over 5,500 women found that younger patients and those who had taken hormone replacement therapy (HRT) were less likely to adhere to their medicine.
NextSource Biotechnology, LLC announced today that Gleostine (lomustine) 5 mg capsules has been approved by the U.S. Food and Drug Administration and is now commercially available in the United States.
› Verified 5 days ago
| Provider Name | Nicole Solk |
|---|---|
| Provider Type | Practitioner - Nurse Practitioner |
| Provider Identifiers | NPI Number: 1013340421 PECOS PAC ID: 5597088971 Enrollment ID: I20190503001616 |
News Archive
Baxa Corporation announces the launch of a new program for sourcing its IntelliFill i.v. Automation and IntelliFlowRx Pharmacy Workflow Manager products. The Baxa IntelliSource(TM) program offers health-system pharmacies access to the automation and software they need to ensure that each dose dispensed is safe and accurate - without making capital investments, paying one-time setup fees or signing capital leases.
The Medical Innovation Bill tabled by Lord Saatchi and currently making its way through the UK's House of Lords "strikes at the heart of evidence-based medicine" and risks "opening the door to the use of less proven, or unproven, approaches such as complementary or alternative medicine", according to a new Editorial published in The Lancet Oncology.
Around 20% of breast cancer patients do not complete prescribed endocrine therapy, researchers report at the ESMO Asia 2016 Congress in Singapore.1 The study in over 5,500 women found that younger patients and those who had taken hormone replacement therapy (HRT) were less likely to adhere to their medicine.
NextSource Biotechnology, LLC announced today that Gleostine (lomustine) 5 mg capsules has been approved by the U.S. Food and Drug Administration and is now commercially available in the United States.
› Verified 5 days ago
| Provider Name | Robert William Macdonald |
|---|---|
| Provider Type | Practitioner - Clinical Social Worker |
| Provider Identifiers | NPI Number: 1710532817 PECOS PAC ID: 7618206095 Enrollment ID: I20190910002782 |
News Archive
Baxa Corporation announces the launch of a new program for sourcing its IntelliFill i.v. Automation and IntelliFlowRx Pharmacy Workflow Manager products. The Baxa IntelliSource(TM) program offers health-system pharmacies access to the automation and software they need to ensure that each dose dispensed is safe and accurate - without making capital investments, paying one-time setup fees or signing capital leases.
The Medical Innovation Bill tabled by Lord Saatchi and currently making its way through the UK's House of Lords "strikes at the heart of evidence-based medicine" and risks "opening the door to the use of less proven, or unproven, approaches such as complementary or alternative medicine", according to a new Editorial published in The Lancet Oncology.
Around 20% of breast cancer patients do not complete prescribed endocrine therapy, researchers report at the ESMO Asia 2016 Congress in Singapore.1 The study in over 5,500 women found that younger patients and those who had taken hormone replacement therapy (HRT) were less likely to adhere to their medicine.
NextSource Biotechnology, LLC announced today that Gleostine (lomustine) 5 mg capsules has been approved by the U.S. Food and Drug Administration and is now commercially available in the United States.
› Verified 5 days ago
| Provider Name | Monica L O'brien |
|---|---|
| Provider Type | Practitioner - Nurse Practitioner |
| Provider Identifiers | NPI Number: 1639459498 PECOS PAC ID: 9638467483 Enrollment ID: I20191021001885 |
News Archive
Baxa Corporation announces the launch of a new program for sourcing its IntelliFill i.v. Automation and IntelliFlowRx Pharmacy Workflow Manager products. The Baxa IntelliSource(TM) program offers health-system pharmacies access to the automation and software they need to ensure that each dose dispensed is safe and accurate - without making capital investments, paying one-time setup fees or signing capital leases.
The Medical Innovation Bill tabled by Lord Saatchi and currently making its way through the UK's House of Lords "strikes at the heart of evidence-based medicine" and risks "opening the door to the use of less proven, or unproven, approaches such as complementary or alternative medicine", according to a new Editorial published in The Lancet Oncology.
Around 20% of breast cancer patients do not complete prescribed endocrine therapy, researchers report at the ESMO Asia 2016 Congress in Singapore.1 The study in over 5,500 women found that younger patients and those who had taken hormone replacement therapy (HRT) were less likely to adhere to their medicine.
NextSource Biotechnology, LLC announced today that Gleostine (lomustine) 5 mg capsules has been approved by the U.S. Food and Drug Administration and is now commercially available in the United States.
› Verified 5 days ago
| Provider Name | Timur-metin Mujdaba |
|---|---|
| Provider Type | Practitioner - Psychiatry |
| Provider Identifiers | NPI Number: 1831570092 PECOS PAC ID: 3476885807 Enrollment ID: I20191104002399 |
News Archive
Baxa Corporation announces the launch of a new program for sourcing its IntelliFill i.v. Automation and IntelliFlowRx Pharmacy Workflow Manager products. The Baxa IntelliSource(TM) program offers health-system pharmacies access to the automation and software they need to ensure that each dose dispensed is safe and accurate - without making capital investments, paying one-time setup fees or signing capital leases.
The Medical Innovation Bill tabled by Lord Saatchi and currently making its way through the UK's House of Lords "strikes at the heart of evidence-based medicine" and risks "opening the door to the use of less proven, or unproven, approaches such as complementary or alternative medicine", according to a new Editorial published in The Lancet Oncology.
Around 20% of breast cancer patients do not complete prescribed endocrine therapy, researchers report at the ESMO Asia 2016 Congress in Singapore.1 The study in over 5,500 women found that younger patients and those who had taken hormone replacement therapy (HRT) were less likely to adhere to their medicine.
NextSource Biotechnology, LLC announced today that Gleostine (lomustine) 5 mg capsules has been approved by the U.S. Food and Drug Administration and is now commercially available in the United States.
› Verified 5 days ago
| Provider Name | Katharine Costa |
|---|---|
| Provider Type | Practitioner - Nurse Practitioner |
| Provider Identifiers | NPI Number: 1548749682 PECOS PAC ID: 1456787068 Enrollment ID: I20200130000235 |
News Archive
Baxa Corporation announces the launch of a new program for sourcing its IntelliFill i.v. Automation and IntelliFlowRx Pharmacy Workflow Manager products. The Baxa IntelliSource(TM) program offers health-system pharmacies access to the automation and software they need to ensure that each dose dispensed is safe and accurate - without making capital investments, paying one-time setup fees or signing capital leases.
The Medical Innovation Bill tabled by Lord Saatchi and currently making its way through the UK's House of Lords "strikes at the heart of evidence-based medicine" and risks "opening the door to the use of less proven, or unproven, approaches such as complementary or alternative medicine", according to a new Editorial published in The Lancet Oncology.
Around 20% of breast cancer patients do not complete prescribed endocrine therapy, researchers report at the ESMO Asia 2016 Congress in Singapore.1 The study in over 5,500 women found that younger patients and those who had taken hormone replacement therapy (HRT) were less likely to adhere to their medicine.
NextSource Biotechnology, LLC announced today that Gleostine (lomustine) 5 mg capsules has been approved by the U.S. Food and Drug Administration and is now commercially available in the United States.
› Verified 5 days ago
| Provider Name | Cindy Marie Coite |
|---|---|
| Provider Type | Practitioner - Clinical Social Worker |
| Provider Identifiers | NPI Number: 1942491923 PECOS PAC ID: 5698102960 Enrollment ID: I20200226001098 |
News Archive
Baxa Corporation announces the launch of a new program for sourcing its IntelliFill i.v. Automation and IntelliFlowRx Pharmacy Workflow Manager products. The Baxa IntelliSource(TM) program offers health-system pharmacies access to the automation and software they need to ensure that each dose dispensed is safe and accurate - without making capital investments, paying one-time setup fees or signing capital leases.
The Medical Innovation Bill tabled by Lord Saatchi and currently making its way through the UK's House of Lords "strikes at the heart of evidence-based medicine" and risks "opening the door to the use of less proven, or unproven, approaches such as complementary or alternative medicine", according to a new Editorial published in The Lancet Oncology.
Around 20% of breast cancer patients do not complete prescribed endocrine therapy, researchers report at the ESMO Asia 2016 Congress in Singapore.1 The study in over 5,500 women found that younger patients and those who had taken hormone replacement therapy (HRT) were less likely to adhere to their medicine.
NextSource Biotechnology, LLC announced today that Gleostine (lomustine) 5 mg capsules has been approved by the U.S. Food and Drug Administration and is now commercially available in the United States.
› Verified 5 days ago
| Provider Name | Thomas Defanti |
|---|---|
| Provider Type | Practitioner - Addiction Medicine |
| Provider Identifiers | NPI Number: 1043239783 PECOS PAC ID: 2668416512 Enrollment ID: I20210120002853 |
News Archive
Baxa Corporation announces the launch of a new program for sourcing its IntelliFill i.v. Automation and IntelliFlowRx Pharmacy Workflow Manager products. The Baxa IntelliSource(TM) program offers health-system pharmacies access to the automation and software they need to ensure that each dose dispensed is safe and accurate - without making capital investments, paying one-time setup fees or signing capital leases.
The Medical Innovation Bill tabled by Lord Saatchi and currently making its way through the UK's House of Lords "strikes at the heart of evidence-based medicine" and risks "opening the door to the use of less proven, or unproven, approaches such as complementary or alternative medicine", according to a new Editorial published in The Lancet Oncology.
Around 20% of breast cancer patients do not complete prescribed endocrine therapy, researchers report at the ESMO Asia 2016 Congress in Singapore.1 The study in over 5,500 women found that younger patients and those who had taken hormone replacement therapy (HRT) were less likely to adhere to their medicine.
NextSource Biotechnology, LLC announced today that Gleostine (lomustine) 5 mg capsules has been approved by the U.S. Food and Drug Administration and is now commercially available in the United States.
› Verified 5 days ago
| Provider Name | Mahmood Hussain Sharfi |
|---|---|
| Provider Type | Practitioner - Psychiatry |
| Provider Identifiers | NPI Number: 1154311611 PECOS PAC ID: 6901823897 Enrollment ID: I20210122001072 |
News Archive
Baxa Corporation announces the launch of a new program for sourcing its IntelliFill i.v. Automation and IntelliFlowRx Pharmacy Workflow Manager products. The Baxa IntelliSource(TM) program offers health-system pharmacies access to the automation and software they need to ensure that each dose dispensed is safe and accurate - without making capital investments, paying one-time setup fees or signing capital leases.
The Medical Innovation Bill tabled by Lord Saatchi and currently making its way through the UK's House of Lords "strikes at the heart of evidence-based medicine" and risks "opening the door to the use of less proven, or unproven, approaches such as complementary or alternative medicine", according to a new Editorial published in The Lancet Oncology.
Around 20% of breast cancer patients do not complete prescribed endocrine therapy, researchers report at the ESMO Asia 2016 Congress in Singapore.1 The study in over 5,500 women found that younger patients and those who had taken hormone replacement therapy (HRT) were less likely to adhere to their medicine.
NextSource Biotechnology, LLC announced today that Gleostine (lomustine) 5 mg capsules has been approved by the U.S. Food and Drug Administration and is now commercially available in the United States.
› Verified 5 days ago
| Provider Name | Jessica Belli Castronovo |
|---|---|
| Provider Type | Practitioner - Clinical Social Worker |
| Provider Identifiers | NPI Number: 1740222421 PECOS PAC ID: 9931513363 Enrollment ID: I20210127000118 |
News Archive
Baxa Corporation announces the launch of a new program for sourcing its IntelliFill i.v. Automation and IntelliFlowRx Pharmacy Workflow Manager products. The Baxa IntelliSource(TM) program offers health-system pharmacies access to the automation and software they need to ensure that each dose dispensed is safe and accurate - without making capital investments, paying one-time setup fees or signing capital leases.
The Medical Innovation Bill tabled by Lord Saatchi and currently making its way through the UK's House of Lords "strikes at the heart of evidence-based medicine" and risks "opening the door to the use of less proven, or unproven, approaches such as complementary or alternative medicine", according to a new Editorial published in The Lancet Oncology.
Around 20% of breast cancer patients do not complete prescribed endocrine therapy, researchers report at the ESMO Asia 2016 Congress in Singapore.1 The study in over 5,500 women found that younger patients and those who had taken hormone replacement therapy (HRT) were less likely to adhere to their medicine.
NextSource Biotechnology, LLC announced today that Gleostine (lomustine) 5 mg capsules has been approved by the U.S. Food and Drug Administration and is now commercially available in the United States.
› Verified 5 days ago
| Provider Name | Cindy Rojas |
|---|---|
| Provider Type | Practitioner - Clinical Social Worker |
| Provider Identifiers | NPI Number: 1841833266 PECOS PAC ID: 0749694586 Enrollment ID: I20210205001759 |
News Archive
Baxa Corporation announces the launch of a new program for sourcing its IntelliFill i.v. Automation and IntelliFlowRx Pharmacy Workflow Manager products. The Baxa IntelliSource(TM) program offers health-system pharmacies access to the automation and software they need to ensure that each dose dispensed is safe and accurate - without making capital investments, paying one-time setup fees or signing capital leases.
The Medical Innovation Bill tabled by Lord Saatchi and currently making its way through the UK's House of Lords "strikes at the heart of evidence-based medicine" and risks "opening the door to the use of less proven, or unproven, approaches such as complementary or alternative medicine", according to a new Editorial published in The Lancet Oncology.
Around 20% of breast cancer patients do not complete prescribed endocrine therapy, researchers report at the ESMO Asia 2016 Congress in Singapore.1 The study in over 5,500 women found that younger patients and those who had taken hormone replacement therapy (HRT) were less likely to adhere to their medicine.
NextSource Biotechnology, LLC announced today that Gleostine (lomustine) 5 mg capsules has been approved by the U.S. Food and Drug Administration and is now commercially available in the United States.
› Verified 5 days ago
| Provider Name | Anthony Joseph Paoletta |
|---|---|
| Provider Type | Practitioner - Clinical Social Worker |
| Provider Identifiers | NPI Number: 1861090508 PECOS PAC ID: 1456767482 Enrollment ID: I20210317000044 |
News Archive
Baxa Corporation announces the launch of a new program for sourcing its IntelliFill i.v. Automation and IntelliFlowRx Pharmacy Workflow Manager products. The Baxa IntelliSource(TM) program offers health-system pharmacies access to the automation and software they need to ensure that each dose dispensed is safe and accurate - without making capital investments, paying one-time setup fees or signing capital leases.
The Medical Innovation Bill tabled by Lord Saatchi and currently making its way through the UK's House of Lords "strikes at the heart of evidence-based medicine" and risks "opening the door to the use of less proven, or unproven, approaches such as complementary or alternative medicine", according to a new Editorial published in The Lancet Oncology.
Around 20% of breast cancer patients do not complete prescribed endocrine therapy, researchers report at the ESMO Asia 2016 Congress in Singapore.1 The study in over 5,500 women found that younger patients and those who had taken hormone replacement therapy (HRT) were less likely to adhere to their medicine.
NextSource Biotechnology, LLC announced today that Gleostine (lomustine) 5 mg capsules has been approved by the U.S. Food and Drug Administration and is now commercially available in the United States.
› Verified 5 days ago
| Provider Name | Linda Aguiar |
|---|---|
| Provider Type | Practitioner - Nurse Practitioner |
| Provider Identifiers | NPI Number: 1457965998 PECOS PAC ID: 5890109243 Enrollment ID: I20210402000569 |
News Archive
Baxa Corporation announces the launch of a new program for sourcing its IntelliFill i.v. Automation and IntelliFlowRx Pharmacy Workflow Manager products. The Baxa IntelliSource(TM) program offers health-system pharmacies access to the automation and software they need to ensure that each dose dispensed is safe and accurate - without making capital investments, paying one-time setup fees or signing capital leases.
The Medical Innovation Bill tabled by Lord Saatchi and currently making its way through the UK's House of Lords "strikes at the heart of evidence-based medicine" and risks "opening the door to the use of less proven, or unproven, approaches such as complementary or alternative medicine", according to a new Editorial published in The Lancet Oncology.
Around 20% of breast cancer patients do not complete prescribed endocrine therapy, researchers report at the ESMO Asia 2016 Congress in Singapore.1 The study in over 5,500 women found that younger patients and those who had taken hormone replacement therapy (HRT) were less likely to adhere to their medicine.
NextSource Biotechnology, LLC announced today that Gleostine (lomustine) 5 mg capsules has been approved by the U.S. Food and Drug Administration and is now commercially available in the United States.
› Verified 5 days ago
| Provider Name | Jacquelyn Morgan |
|---|---|
| Provider Type | Practitioner - Clinical Social Worker |
| Provider Identifiers | NPI Number: 1942631858 PECOS PAC ID: 9032527320 Enrollment ID: I20210427001012 |
News Archive
Baxa Corporation announces the launch of a new program for sourcing its IntelliFill i.v. Automation and IntelliFlowRx Pharmacy Workflow Manager products. The Baxa IntelliSource(TM) program offers health-system pharmacies access to the automation and software they need to ensure that each dose dispensed is safe and accurate - without making capital investments, paying one-time setup fees or signing capital leases.
The Medical Innovation Bill tabled by Lord Saatchi and currently making its way through the UK's House of Lords "strikes at the heart of evidence-based medicine" and risks "opening the door to the use of less proven, or unproven, approaches such as complementary or alternative medicine", according to a new Editorial published in The Lancet Oncology.
Around 20% of breast cancer patients do not complete prescribed endocrine therapy, researchers report at the ESMO Asia 2016 Congress in Singapore.1 The study in over 5,500 women found that younger patients and those who had taken hormone replacement therapy (HRT) were less likely to adhere to their medicine.
NextSource Biotechnology, LLC announced today that Gleostine (lomustine) 5 mg capsules has been approved by the U.S. Food and Drug Administration and is now commercially available in the United States.
› Verified 5 days ago
| Provider Name | David Geyer |
|---|---|
| Provider Type | Practitioner - Nurse Practitioner |
| Provider Identifiers | NPI Number: 1063058584 PECOS PAC ID: 0345669016 Enrollment ID: I20210512000696 |
News Archive
Baxa Corporation announces the launch of a new program for sourcing its IntelliFill i.v. Automation and IntelliFlowRx Pharmacy Workflow Manager products. The Baxa IntelliSource(TM) program offers health-system pharmacies access to the automation and software they need to ensure that each dose dispensed is safe and accurate - without making capital investments, paying one-time setup fees or signing capital leases.
The Medical Innovation Bill tabled by Lord Saatchi and currently making its way through the UK's House of Lords "strikes at the heart of evidence-based medicine" and risks "opening the door to the use of less proven, or unproven, approaches such as complementary or alternative medicine", according to a new Editorial published in The Lancet Oncology.
Around 20% of breast cancer patients do not complete prescribed endocrine therapy, researchers report at the ESMO Asia 2016 Congress in Singapore.1 The study in over 5,500 women found that younger patients and those who had taken hormone replacement therapy (HRT) were less likely to adhere to their medicine.
NextSource Biotechnology, LLC announced today that Gleostine (lomustine) 5 mg capsules has been approved by the U.S. Food and Drug Administration and is now commercially available in the United States.
› Verified 5 days ago
| Provider Name | Valerie Marie Almeida Monroe |
|---|---|
| Provider Type | Practitioner - Nurse Practitioner |
| Provider Identifiers | NPI Number: 1275159501 PECOS PAC ID: 7517366404 Enrollment ID: I20210526000714 |
News Archive
Baxa Corporation announces the launch of a new program for sourcing its IntelliFill i.v. Automation and IntelliFlowRx Pharmacy Workflow Manager products. The Baxa IntelliSource(TM) program offers health-system pharmacies access to the automation and software they need to ensure that each dose dispensed is safe and accurate - without making capital investments, paying one-time setup fees or signing capital leases.
The Medical Innovation Bill tabled by Lord Saatchi and currently making its way through the UK's House of Lords "strikes at the heart of evidence-based medicine" and risks "opening the door to the use of less proven, or unproven, approaches such as complementary or alternative medicine", according to a new Editorial published in The Lancet Oncology.
Around 20% of breast cancer patients do not complete prescribed endocrine therapy, researchers report at the ESMO Asia 2016 Congress in Singapore.1 The study in over 5,500 women found that younger patients and those who had taken hormone replacement therapy (HRT) were less likely to adhere to their medicine.
NextSource Biotechnology, LLC announced today that Gleostine (lomustine) 5 mg capsules has been approved by the U.S. Food and Drug Administration and is now commercially available in the United States.
› Verified 5 days ago
| Provider Name | Elkins Guzman |
|---|---|
| Provider Type | Practitioner - Psychiatry |
| Provider Identifiers | NPI Number: 1679952451 PECOS PAC ID: 9830525575 Enrollment ID: I20210825000162 |
News Archive
Baxa Corporation announces the launch of a new program for sourcing its IntelliFill i.v. Automation and IntelliFlowRx Pharmacy Workflow Manager products. The Baxa IntelliSource(TM) program offers health-system pharmacies access to the automation and software they need to ensure that each dose dispensed is safe and accurate - without making capital investments, paying one-time setup fees or signing capital leases.
The Medical Innovation Bill tabled by Lord Saatchi and currently making its way through the UK's House of Lords "strikes at the heart of evidence-based medicine" and risks "opening the door to the use of less proven, or unproven, approaches such as complementary or alternative medicine", according to a new Editorial published in The Lancet Oncology.
Around 20% of breast cancer patients do not complete prescribed endocrine therapy, researchers report at the ESMO Asia 2016 Congress in Singapore.1 The study in over 5,500 women found that younger patients and those who had taken hormone replacement therapy (HRT) were less likely to adhere to their medicine.
NextSource Biotechnology, LLC announced today that Gleostine (lomustine) 5 mg capsules has been approved by the U.S. Food and Drug Administration and is now commercially available in the United States.
› Verified 5 days ago
| Provider Name | Jenna L Butner |
|---|---|
| Provider Type | Practitioner - Addiction Medicine |
| Provider Identifiers | NPI Number: 1316258775 PECOS PAC ID: 3971724170 Enrollment ID: I20210917002656 |
News Archive
Baxa Corporation announces the launch of a new program for sourcing its IntelliFill i.v. Automation and IntelliFlowRx Pharmacy Workflow Manager products. The Baxa IntelliSource(TM) program offers health-system pharmacies access to the automation and software they need to ensure that each dose dispensed is safe and accurate - without making capital investments, paying one-time setup fees or signing capital leases.
The Medical Innovation Bill tabled by Lord Saatchi and currently making its way through the UK's House of Lords "strikes at the heart of evidence-based medicine" and risks "opening the door to the use of less proven, or unproven, approaches such as complementary or alternative medicine", according to a new Editorial published in The Lancet Oncology.
Around 20% of breast cancer patients do not complete prescribed endocrine therapy, researchers report at the ESMO Asia 2016 Congress in Singapore.1 The study in over 5,500 women found that younger patients and those who had taken hormone replacement therapy (HRT) were less likely to adhere to their medicine.
NextSource Biotechnology, LLC announced today that Gleostine (lomustine) 5 mg capsules has been approved by the U.S. Food and Drug Administration and is now commercially available in the United States.
› Verified 5 days ago
| Provider Name | Margot Duchowny |
|---|---|
| Provider Type | Practitioner - Nurse Practitioner |
| Provider Identifiers | NPI Number: 1174286116 PECOS PAC ID: 3870982937 Enrollment ID: I20211110001839 |
News Archive
Baxa Corporation announces the launch of a new program for sourcing its IntelliFill i.v. Automation and IntelliFlowRx Pharmacy Workflow Manager products. The Baxa IntelliSource(TM) program offers health-system pharmacies access to the automation and software they need to ensure that each dose dispensed is safe and accurate - without making capital investments, paying one-time setup fees or signing capital leases.
The Medical Innovation Bill tabled by Lord Saatchi and currently making its way through the UK's House of Lords "strikes at the heart of evidence-based medicine" and risks "opening the door to the use of less proven, or unproven, approaches such as complementary or alternative medicine", according to a new Editorial published in The Lancet Oncology.
Around 20% of breast cancer patients do not complete prescribed endocrine therapy, researchers report at the ESMO Asia 2016 Congress in Singapore.1 The study in over 5,500 women found that younger patients and those who had taken hormone replacement therapy (HRT) were less likely to adhere to their medicine.
NextSource Biotechnology, LLC announced today that Gleostine (lomustine) 5 mg capsules has been approved by the U.S. Food and Drug Administration and is now commercially available in the United States.
› Verified 5 days ago
| Provider Name | Ernest A. Kendrick |
|---|---|
| Provider Type | Practitioner - Psychiatry |
| Provider Identifiers | NPI Number: 1124012067 PECOS PAC ID: 5799828976 Enrollment ID: I20211206001041 |
News Archive
Baxa Corporation announces the launch of a new program for sourcing its IntelliFill i.v. Automation and IntelliFlowRx Pharmacy Workflow Manager products. The Baxa IntelliSource(TM) program offers health-system pharmacies access to the automation and software they need to ensure that each dose dispensed is safe and accurate - without making capital investments, paying one-time setup fees or signing capital leases.
The Medical Innovation Bill tabled by Lord Saatchi and currently making its way through the UK's House of Lords "strikes at the heart of evidence-based medicine" and risks "opening the door to the use of less proven, or unproven, approaches such as complementary or alternative medicine", according to a new Editorial published in The Lancet Oncology.
Around 20% of breast cancer patients do not complete prescribed endocrine therapy, researchers report at the ESMO Asia 2016 Congress in Singapore.1 The study in over 5,500 women found that younger patients and those who had taken hormone replacement therapy (HRT) were less likely to adhere to their medicine.
NextSource Biotechnology, LLC announced today that Gleostine (lomustine) 5 mg capsules has been approved by the U.S. Food and Drug Administration and is now commercially available in the United States.
› Verified 5 days ago
| Provider Name | Juan Gan |
|---|---|
| Provider Type | Practitioner - Psychiatry |
| Provider Identifiers | NPI Number: 1801001136 PECOS PAC ID: 7911226931 Enrollment ID: I20211214002553 |
News Archive
Baxa Corporation announces the launch of a new program for sourcing its IntelliFill i.v. Automation and IntelliFlowRx Pharmacy Workflow Manager products. The Baxa IntelliSource(TM) program offers health-system pharmacies access to the automation and software they need to ensure that each dose dispensed is safe and accurate - without making capital investments, paying one-time setup fees or signing capital leases.
The Medical Innovation Bill tabled by Lord Saatchi and currently making its way through the UK's House of Lords "strikes at the heart of evidence-based medicine" and risks "opening the door to the use of less proven, or unproven, approaches such as complementary or alternative medicine", according to a new Editorial published in The Lancet Oncology.
Around 20% of breast cancer patients do not complete prescribed endocrine therapy, researchers report at the ESMO Asia 2016 Congress in Singapore.1 The study in over 5,500 women found that younger patients and those who had taken hormone replacement therapy (HRT) were less likely to adhere to their medicine.
NextSource Biotechnology, LLC announced today that Gleostine (lomustine) 5 mg capsules has been approved by the U.S. Food and Drug Administration and is now commercially available in the United States.
› Verified 5 days ago
| Provider Name | Emily Susan Rupert |
|---|---|
| Provider Type | Practitioner - Clinical Social Worker |
| Provider Identifiers | NPI Number: 1912665001 PECOS PAC ID: 1951793439 Enrollment ID: I20220112002056 |
News Archive
Baxa Corporation announces the launch of a new program for sourcing its IntelliFill i.v. Automation and IntelliFlowRx Pharmacy Workflow Manager products. The Baxa IntelliSource(TM) program offers health-system pharmacies access to the automation and software they need to ensure that each dose dispensed is safe and accurate - without making capital investments, paying one-time setup fees or signing capital leases.
The Medical Innovation Bill tabled by Lord Saatchi and currently making its way through the UK's House of Lords "strikes at the heart of evidence-based medicine" and risks "opening the door to the use of less proven, or unproven, approaches such as complementary or alternative medicine", according to a new Editorial published in The Lancet Oncology.
Around 20% of breast cancer patients do not complete prescribed endocrine therapy, researchers report at the ESMO Asia 2016 Congress in Singapore.1 The study in over 5,500 women found that younger patients and those who had taken hormone replacement therapy (HRT) were less likely to adhere to their medicine.
NextSource Biotechnology, LLC announced today that Gleostine (lomustine) 5 mg capsules has been approved by the U.S. Food and Drug Administration and is now commercially available in the United States.
› Verified 5 days ago
| Provider Name | Jon Dooley |
|---|---|
| Provider Type | Practitioner - Pediatric Medicine |
| Provider Identifiers | NPI Number: 1619472339 PECOS PAC ID: 1951645472 Enrollment ID: I20220125000843 |
News Archive
Baxa Corporation announces the launch of a new program for sourcing its IntelliFill i.v. Automation and IntelliFlowRx Pharmacy Workflow Manager products. The Baxa IntelliSource(TM) program offers health-system pharmacies access to the automation and software they need to ensure that each dose dispensed is safe and accurate - without making capital investments, paying one-time setup fees or signing capital leases.
The Medical Innovation Bill tabled by Lord Saatchi and currently making its way through the UK's House of Lords "strikes at the heart of evidence-based medicine" and risks "opening the door to the use of less proven, or unproven, approaches such as complementary or alternative medicine", according to a new Editorial published in The Lancet Oncology.
Around 20% of breast cancer patients do not complete prescribed endocrine therapy, researchers report at the ESMO Asia 2016 Congress in Singapore.1 The study in over 5,500 women found that younger patients and those who had taken hormone replacement therapy (HRT) were less likely to adhere to their medicine.
NextSource Biotechnology, LLC announced today that Gleostine (lomustine) 5 mg capsules has been approved by the U.S. Food and Drug Administration and is now commercially available in the United States.
› Verified 5 days ago
| Provider Name | Ashley Collins |
|---|---|
| Provider Type | Practitioner - Psychiatry |
| Provider Identifiers | NPI Number: 1457747933 PECOS PAC ID: 1254671191 Enrollment ID: I20220329001024 |
News Archive
Baxa Corporation announces the launch of a new program for sourcing its IntelliFill i.v. Automation and IntelliFlowRx Pharmacy Workflow Manager products. The Baxa IntelliSource(TM) program offers health-system pharmacies access to the automation and software they need to ensure that each dose dispensed is safe and accurate - without making capital investments, paying one-time setup fees or signing capital leases.
The Medical Innovation Bill tabled by Lord Saatchi and currently making its way through the UK's House of Lords "strikes at the heart of evidence-based medicine" and risks "opening the door to the use of less proven, or unproven, approaches such as complementary or alternative medicine", according to a new Editorial published in The Lancet Oncology.
Around 20% of breast cancer patients do not complete prescribed endocrine therapy, researchers report at the ESMO Asia 2016 Congress in Singapore.1 The study in over 5,500 women found that younger patients and those who had taken hormone replacement therapy (HRT) were less likely to adhere to their medicine.
NextSource Biotechnology, LLC announced today that Gleostine (lomustine) 5 mg capsules has been approved by the U.S. Food and Drug Administration and is now commercially available in the United States.
› Verified 5 days ago
| Provider Name | Mohammed Siddiqui |
|---|---|
| Provider Type | Practitioner - Psychiatry |
| Provider Identifiers | NPI Number: 1639456122 PECOS PAC ID: 8729224720 Enrollment ID: I20220621000606 |
News Archive
Baxa Corporation announces the launch of a new program for sourcing its IntelliFill i.v. Automation and IntelliFlowRx Pharmacy Workflow Manager products. The Baxa IntelliSource(TM) program offers health-system pharmacies access to the automation and software they need to ensure that each dose dispensed is safe and accurate - without making capital investments, paying one-time setup fees or signing capital leases.
The Medical Innovation Bill tabled by Lord Saatchi and currently making its way through the UK's House of Lords "strikes at the heart of evidence-based medicine" and risks "opening the door to the use of less proven, or unproven, approaches such as complementary or alternative medicine", according to a new Editorial published in The Lancet Oncology.
Around 20% of breast cancer patients do not complete prescribed endocrine therapy, researchers report at the ESMO Asia 2016 Congress in Singapore.1 The study in over 5,500 women found that younger patients and those who had taken hormone replacement therapy (HRT) were less likely to adhere to their medicine.
NextSource Biotechnology, LLC announced today that Gleostine (lomustine) 5 mg capsules has been approved by the U.S. Food and Drug Administration and is now commercially available in the United States.
› Verified 5 days ago
| Provider Name | Uchechukwu Ugorji |
|---|---|
| Provider Type | Practitioner - Psychiatry |
| Provider Identifiers | NPI Number: 1033695986 PECOS PAC ID: 2567848583 Enrollment ID: I20220928003039 |
News Archive
Baxa Corporation announces the launch of a new program for sourcing its IntelliFill i.v. Automation and IntelliFlowRx Pharmacy Workflow Manager products. The Baxa IntelliSource(TM) program offers health-system pharmacies access to the automation and software they need to ensure that each dose dispensed is safe and accurate - without making capital investments, paying one-time setup fees or signing capital leases.
The Medical Innovation Bill tabled by Lord Saatchi and currently making its way through the UK's House of Lords "strikes at the heart of evidence-based medicine" and risks "opening the door to the use of less proven, or unproven, approaches such as complementary or alternative medicine", according to a new Editorial published in The Lancet Oncology.
Around 20% of breast cancer patients do not complete prescribed endocrine therapy, researchers report at the ESMO Asia 2016 Congress in Singapore.1 The study in over 5,500 women found that younger patients and those who had taken hormone replacement therapy (HRT) were less likely to adhere to their medicine.
NextSource Biotechnology, LLC announced today that Gleostine (lomustine) 5 mg capsules has been approved by the U.S. Food and Drug Administration and is now commercially available in the United States.
› Verified 5 days ago
| Provider Name | Alice M Colon |
|---|---|
| Provider Type | Practitioner - Clinical Social Worker |
| Provider Identifiers | NPI Number: 1093471054 PECOS PAC ID: 6507242294 Enrollment ID: I20221004001368 |
News Archive
Baxa Corporation announces the launch of a new program for sourcing its IntelliFill i.v. Automation and IntelliFlowRx Pharmacy Workflow Manager products. The Baxa IntelliSource(TM) program offers health-system pharmacies access to the automation and software they need to ensure that each dose dispensed is safe and accurate - without making capital investments, paying one-time setup fees or signing capital leases.
The Medical Innovation Bill tabled by Lord Saatchi and currently making its way through the UK's House of Lords "strikes at the heart of evidence-based medicine" and risks "opening the door to the use of less proven, or unproven, approaches such as complementary or alternative medicine", according to a new Editorial published in The Lancet Oncology.
Around 20% of breast cancer patients do not complete prescribed endocrine therapy, researchers report at the ESMO Asia 2016 Congress in Singapore.1 The study in over 5,500 women found that younger patients and those who had taken hormone replacement therapy (HRT) were less likely to adhere to their medicine.
NextSource Biotechnology, LLC announced today that Gleostine (lomustine) 5 mg capsules has been approved by the U.S. Food and Drug Administration and is now commercially available in the United States.
› Verified 5 days ago
| Provider Name | Stephanie Connor |
|---|---|
| Provider Type | Practitioner - Nurse Practitioner |
| Provider Identifiers | NPI Number: 1073251039 PECOS PAC ID: 8325416027 Enrollment ID: I20221201000050 |
News Archive
Baxa Corporation announces the launch of a new program for sourcing its IntelliFill i.v. Automation and IntelliFlowRx Pharmacy Workflow Manager products. The Baxa IntelliSource(TM) program offers health-system pharmacies access to the automation and software they need to ensure that each dose dispensed is safe and accurate - without making capital investments, paying one-time setup fees or signing capital leases.
The Medical Innovation Bill tabled by Lord Saatchi and currently making its way through the UK's House of Lords "strikes at the heart of evidence-based medicine" and risks "opening the door to the use of less proven, or unproven, approaches such as complementary or alternative medicine", according to a new Editorial published in The Lancet Oncology.
Around 20% of breast cancer patients do not complete prescribed endocrine therapy, researchers report at the ESMO Asia 2016 Congress in Singapore.1 The study in over 5,500 women found that younger patients and those who had taken hormone replacement therapy (HRT) were less likely to adhere to their medicine.
NextSource Biotechnology, LLC announced today that Gleostine (lomustine) 5 mg capsules has been approved by the U.S. Food and Drug Administration and is now commercially available in the United States.
› Verified 5 days ago
| Provider Name | Robinson Pierre-louis |
|---|---|
| Provider Type | Practitioner - Nurse Practitioner |
| Provider Identifiers | NPI Number: 1649856022 PECOS PAC ID: 6103295431 Enrollment ID: I20221208002300 |
News Archive
Baxa Corporation announces the launch of a new program for sourcing its IntelliFill i.v. Automation and IntelliFlowRx Pharmacy Workflow Manager products. The Baxa IntelliSource(TM) program offers health-system pharmacies access to the automation and software they need to ensure that each dose dispensed is safe and accurate - without making capital investments, paying one-time setup fees or signing capital leases.
The Medical Innovation Bill tabled by Lord Saatchi and currently making its way through the UK's House of Lords "strikes at the heart of evidence-based medicine" and risks "opening the door to the use of less proven, or unproven, approaches such as complementary or alternative medicine", according to a new Editorial published in The Lancet Oncology.
Around 20% of breast cancer patients do not complete prescribed endocrine therapy, researchers report at the ESMO Asia 2016 Congress in Singapore.1 The study in over 5,500 women found that younger patients and those who had taken hormone replacement therapy (HRT) were less likely to adhere to their medicine.
NextSource Biotechnology, LLC announced today that Gleostine (lomustine) 5 mg capsules has been approved by the U.S. Food and Drug Administration and is now commercially available in the United States.
› Verified 5 days ago
| Provider Name | Natalia M. Arboleda |
|---|---|
| Provider Type | Practitioner - Nurse Practitioner |
| Provider Identifiers | NPI Number: 1639823057 PECOS PAC ID: 5698130888 Enrollment ID: I20230421001340 |
News Archive
Baxa Corporation announces the launch of a new program for sourcing its IntelliFill i.v. Automation and IntelliFlowRx Pharmacy Workflow Manager products. The Baxa IntelliSource(TM) program offers health-system pharmacies access to the automation and software they need to ensure that each dose dispensed is safe and accurate - without making capital investments, paying one-time setup fees or signing capital leases.
The Medical Innovation Bill tabled by Lord Saatchi and currently making its way through the UK's House of Lords "strikes at the heart of evidence-based medicine" and risks "opening the door to the use of less proven, or unproven, approaches such as complementary or alternative medicine", according to a new Editorial published in The Lancet Oncology.
Around 20% of breast cancer patients do not complete prescribed endocrine therapy, researchers report at the ESMO Asia 2016 Congress in Singapore.1 The study in over 5,500 women found that younger patients and those who had taken hormone replacement therapy (HRT) were less likely to adhere to their medicine.
NextSource Biotechnology, LLC announced today that Gleostine (lomustine) 5 mg capsules has been approved by the U.S. Food and Drug Administration and is now commercially available in the United States.
› Verified 5 days ago
| Provider Name | Carmen Benjamin |
|---|---|
| Provider Type | Practitioner - Clinical Social Worker |
| Provider Identifiers | NPI Number: 1063905180 PECOS PAC ID: 1759756406 Enrollment ID: I20230530001025 |
News Archive
Baxa Corporation announces the launch of a new program for sourcing its IntelliFill i.v. Automation and IntelliFlowRx Pharmacy Workflow Manager products. The Baxa IntelliSource(TM) program offers health-system pharmacies access to the automation and software they need to ensure that each dose dispensed is safe and accurate - without making capital investments, paying one-time setup fees or signing capital leases.
The Medical Innovation Bill tabled by Lord Saatchi and currently making its way through the UK's House of Lords "strikes at the heart of evidence-based medicine" and risks "opening the door to the use of less proven, or unproven, approaches such as complementary or alternative medicine", according to a new Editorial published in The Lancet Oncology.
Around 20% of breast cancer patients do not complete prescribed endocrine therapy, researchers report at the ESMO Asia 2016 Congress in Singapore.1 The study in over 5,500 women found that younger patients and those who had taken hormone replacement therapy (HRT) were less likely to adhere to their medicine.
NextSource Biotechnology, LLC announced today that Gleostine (lomustine) 5 mg capsules has been approved by the U.S. Food and Drug Administration and is now commercially available in the United States.
› Verified 5 days ago
| Provider Name | Ralph Eugene |
|---|---|
| Provider Type | Practitioner - Nurse Practitioner |
| Provider Identifiers | NPI Number: 1225435829 PECOS PAC ID: 8123495595 Enrollment ID: I20230607001402 |
News Archive
Baxa Corporation announces the launch of a new program for sourcing its IntelliFill i.v. Automation and IntelliFlowRx Pharmacy Workflow Manager products. The Baxa IntelliSource(TM) program offers health-system pharmacies access to the automation and software they need to ensure that each dose dispensed is safe and accurate - without making capital investments, paying one-time setup fees or signing capital leases.
The Medical Innovation Bill tabled by Lord Saatchi and currently making its way through the UK's House of Lords "strikes at the heart of evidence-based medicine" and risks "opening the door to the use of less proven, or unproven, approaches such as complementary or alternative medicine", according to a new Editorial published in The Lancet Oncology.
Around 20% of breast cancer patients do not complete prescribed endocrine therapy, researchers report at the ESMO Asia 2016 Congress in Singapore.1 The study in over 5,500 women found that younger patients and those who had taken hormone replacement therapy (HRT) were less likely to adhere to their medicine.
NextSource Biotechnology, LLC announced today that Gleostine (lomustine) 5 mg capsules has been approved by the U.S. Food and Drug Administration and is now commercially available in the United States.
› Verified 5 days ago
| Provider Name | Melissa Muriel |
|---|---|
| Provider Type | Practitioner - Nurse Practitioner |
| Provider Identifiers | NPI Number: 1265154850 PECOS PAC ID: 9335518620 Enrollment ID: I20230705002264 |
News Archive
Baxa Corporation announces the launch of a new program for sourcing its IntelliFill i.v. Automation and IntelliFlowRx Pharmacy Workflow Manager products. The Baxa IntelliSource(TM) program offers health-system pharmacies access to the automation and software they need to ensure that each dose dispensed is safe and accurate - without making capital investments, paying one-time setup fees or signing capital leases.
The Medical Innovation Bill tabled by Lord Saatchi and currently making its way through the UK's House of Lords "strikes at the heart of evidence-based medicine" and risks "opening the door to the use of less proven, or unproven, approaches such as complementary or alternative medicine", according to a new Editorial published in The Lancet Oncology.
Around 20% of breast cancer patients do not complete prescribed endocrine therapy, researchers report at the ESMO Asia 2016 Congress in Singapore.1 The study in over 5,500 women found that younger patients and those who had taken hormone replacement therapy (HRT) were less likely to adhere to their medicine.
NextSource Biotechnology, LLC announced today that Gleostine (lomustine) 5 mg capsules has been approved by the U.S. Food and Drug Administration and is now commercially available in the United States.
› Verified 5 days ago
| Provider Name | Lisbeth Rosario |
|---|---|
| Provider Type | Practitioner - Clinical Social Worker |
| Provider Identifiers | NPI Number: 1063196376 PECOS PAC ID: 5991164923 Enrollment ID: I20230707003175 |
News Archive
Baxa Corporation announces the launch of a new program for sourcing its IntelliFill i.v. Automation and IntelliFlowRx Pharmacy Workflow Manager products. The Baxa IntelliSource(TM) program offers health-system pharmacies access to the automation and software they need to ensure that each dose dispensed is safe and accurate - without making capital investments, paying one-time setup fees or signing capital leases.
The Medical Innovation Bill tabled by Lord Saatchi and currently making its way through the UK's House of Lords "strikes at the heart of evidence-based medicine" and risks "opening the door to the use of less proven, or unproven, approaches such as complementary or alternative medicine", according to a new Editorial published in The Lancet Oncology.
Around 20% of breast cancer patients do not complete prescribed endocrine therapy, researchers report at the ESMO Asia 2016 Congress in Singapore.1 The study in over 5,500 women found that younger patients and those who had taken hormone replacement therapy (HRT) were less likely to adhere to their medicine.
NextSource Biotechnology, LLC announced today that Gleostine (lomustine) 5 mg capsules has been approved by the U.S. Food and Drug Administration and is now commercially available in the United States.
› Verified 5 days ago
| Provider Name | Jeremy Parker |
|---|---|
| Provider Type | Practitioner - Psychiatry |
| Provider Identifiers | NPI Number: 1780027888 PECOS PAC ID: 6507162906 Enrollment ID: I20230919000868 |
News Archive
Baxa Corporation announces the launch of a new program for sourcing its IntelliFill i.v. Automation and IntelliFlowRx Pharmacy Workflow Manager products. The Baxa IntelliSource(TM) program offers health-system pharmacies access to the automation and software they need to ensure that each dose dispensed is safe and accurate - without making capital investments, paying one-time setup fees or signing capital leases.
The Medical Innovation Bill tabled by Lord Saatchi and currently making its way through the UK's House of Lords "strikes at the heart of evidence-based medicine" and risks "opening the door to the use of less proven, or unproven, approaches such as complementary or alternative medicine", according to a new Editorial published in The Lancet Oncology.
Around 20% of breast cancer patients do not complete prescribed endocrine therapy, researchers report at the ESMO Asia 2016 Congress in Singapore.1 The study in over 5,500 women found that younger patients and those who had taken hormone replacement therapy (HRT) were less likely to adhere to their medicine.
NextSource Biotechnology, LLC announced today that Gleostine (lomustine) 5 mg capsules has been approved by the U.S. Food and Drug Administration and is now commercially available in the United States.
› Verified 5 days ago
| Provider Name | Jason Lawrence Franklin |
|---|---|
| Provider Type | Practitioner - Clinical Social Worker |
| Provider Identifiers | NPI Number: 1639941263 PECOS PAC ID: 4688023757 Enrollment ID: I20231214001910 |
News Archive
Baxa Corporation announces the launch of a new program for sourcing its IntelliFill i.v. Automation and IntelliFlowRx Pharmacy Workflow Manager products. The Baxa IntelliSource(TM) program offers health-system pharmacies access to the automation and software they need to ensure that each dose dispensed is safe and accurate - without making capital investments, paying one-time setup fees or signing capital leases.
The Medical Innovation Bill tabled by Lord Saatchi and currently making its way through the UK's House of Lords "strikes at the heart of evidence-based medicine" and risks "opening the door to the use of less proven, or unproven, approaches such as complementary or alternative medicine", according to a new Editorial published in The Lancet Oncology.
Around 20% of breast cancer patients do not complete prescribed endocrine therapy, researchers report at the ESMO Asia 2016 Congress in Singapore.1 The study in over 5,500 women found that younger patients and those who had taken hormone replacement therapy (HRT) were less likely to adhere to their medicine.
NextSource Biotechnology, LLC announced today that Gleostine (lomustine) 5 mg capsules has been approved by the U.S. Food and Drug Administration and is now commercially available in the United States.
› Verified 5 days ago
| Provider Name | Kate Bowen |
|---|---|
| Provider Type | Practitioner - Mental Health Counselor |
| Provider Identifiers | NPI Number: 1285872101 PECOS PAC ID: 6204289770 Enrollment ID: I20240131003419 |
News Archive
Baxa Corporation announces the launch of a new program for sourcing its IntelliFill i.v. Automation and IntelliFlowRx Pharmacy Workflow Manager products. The Baxa IntelliSource(TM) program offers health-system pharmacies access to the automation and software they need to ensure that each dose dispensed is safe and accurate - without making capital investments, paying one-time setup fees or signing capital leases.
The Medical Innovation Bill tabled by Lord Saatchi and currently making its way through the UK's House of Lords "strikes at the heart of evidence-based medicine" and risks "opening the door to the use of less proven, or unproven, approaches such as complementary or alternative medicine", according to a new Editorial published in The Lancet Oncology.
Around 20% of breast cancer patients do not complete prescribed endocrine therapy, researchers report at the ESMO Asia 2016 Congress in Singapore.1 The study in over 5,500 women found that younger patients and those who had taken hormone replacement therapy (HRT) were less likely to adhere to their medicine.
NextSource Biotechnology, LLC announced today that Gleostine (lomustine) 5 mg capsules has been approved by the U.S. Food and Drug Administration and is now commercially available in the United States.
› Verified 5 days ago
| Provider Name | Valerie Jean Zuercher |
|---|---|
| Provider Type | Practitioner - Clinical Social Worker |
| Provider Identifiers | NPI Number: 1023889391 PECOS PAC ID: 9638515109 Enrollment ID: I20240307001380 |
News Archive
Baxa Corporation announces the launch of a new program for sourcing its IntelliFill i.v. Automation and IntelliFlowRx Pharmacy Workflow Manager products. The Baxa IntelliSource(TM) program offers health-system pharmacies access to the automation and software they need to ensure that each dose dispensed is safe and accurate - without making capital investments, paying one-time setup fees or signing capital leases.
The Medical Innovation Bill tabled by Lord Saatchi and currently making its way through the UK's House of Lords "strikes at the heart of evidence-based medicine" and risks "opening the door to the use of less proven, or unproven, approaches such as complementary or alternative medicine", according to a new Editorial published in The Lancet Oncology.
Around 20% of breast cancer patients do not complete prescribed endocrine therapy, researchers report at the ESMO Asia 2016 Congress in Singapore.1 The study in over 5,500 women found that younger patients and those who had taken hormone replacement therapy (HRT) were less likely to adhere to their medicine.
NextSource Biotechnology, LLC announced today that Gleostine (lomustine) 5 mg capsules has been approved by the U.S. Food and Drug Administration and is now commercially available in the United States.
› Verified 5 days ago
News Archive
Baxa Corporation announces the launch of a new program for sourcing its IntelliFill i.v. Automation and IntelliFlowRx Pharmacy Workflow Manager products. The Baxa IntelliSource(TM) program offers health-system pharmacies access to the automation and software they need to ensure that each dose dispensed is safe and accurate - without making capital investments, paying one-time setup fees or signing capital leases.
The Medical Innovation Bill tabled by Lord Saatchi and currently making its way through the UK's House of Lords "strikes at the heart of evidence-based medicine" and risks "opening the door to the use of less proven, or unproven, approaches such as complementary or alternative medicine", according to a new Editorial published in The Lancet Oncology.
Around 20% of breast cancer patients do not complete prescribed endocrine therapy, researchers report at the ESMO Asia 2016 Congress in Singapore.1 The study in over 5,500 women found that younger patients and those who had taken hormone replacement therapy (HRT) were less likely to adhere to their medicine.
NextSource Biotechnology, LLC announced today that Gleostine (lomustine) 5 mg capsules has been approved by the U.S. Food and Drug Administration and is now commercially available in the United States.
› Verified 5 days ago
Rosalino Counseling Services Mental Health Clinic Medicare: Not Enrolled in Medicare Practice Location: 1052 Charles St, Apt 2, North Providence, RI 02904 Phone: 401-419-4846 | |
Psychiatric Health Services Mental Health Clinic Medicare: Not Enrolled in Medicare Practice Location: 200 High Service Ave, North Providence, RI 02904 Phone: 401-456-3649 Fax: 401-752-8116 | |
Healthy Expressions Llc Mental Health Clinic Medicare: Not Enrolled in Medicare Practice Location: 10 Miner St, North Providence, RI 02904 Phone: 401-660-6815 | |
St. Joseph Health Center Mental Health Clinic Medicare: Medicare Enrolled Practice Location: 200 High Service Ave, North Providence, RI 02904 Phone: 401-456-3000 Fax: 401-456-3028 | |
Gina M. Iaciofano, Llc Mental Health Clinic Medicare: Not Enrolled in Medicare Practice Location: 1920 Mineral Spring Ave, Unit 9, North Providence, RI 02904 Phone: 401-497-6500 | |
Clear Mind Counseling Llc Mental Health Clinic Medicare: Medicare Enrolled Practice Location: 8 Hillview Dr, North Providence, RI 02904 Phone: 508-216-0077 Fax: 508-507-3350 |